RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 3 of 77 SYNOPSIS  
Protocol Title:  A Multicenter, Randomized, Dose -Ranging,  
Double-Masked, Placebo -Controlled Phase 2 Study 
Evaluating the Safety and Efficacy of RTA 408 
Ophthalmic Suspension for the Treatment of Ocular 
Inflammation and Pain following Ocular Surgery  
Protocol Number:  408-C-1307 
Study Drug : 1) RTA 408 Ophthalmic Suspension 0.5%  
2) RTA 408 Ophthalmic Suspension 1.0%  
3) Placebo  for RTA 408 Ophthalmic Suspension  
Study Phase : Phase 2  
Primary Objective: To evaluate the clinical efficacy and safety of  two 
concentrations of RTA 408 Ophthalmic Suspension against placebo  in the treatment of patient s with 
inflammation and pain following  ocular surgery  
Secondary Objective: None 
Overall Study Design  
Structure:  Multi-center, double-masked, randomized, placebo -
controlled, dose- ranging, efficacy study   
Duration: Approximately 21 to 49 days ( 6 study visits)  
Controls: Placebo for RTA 408 Ophthalmic Suspension  
57$2SKWKDOPLF6XVSHQVLR Q     5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO&     $PHQGPHQW)HE 

&RQILGHQWLDO  3DJHRI 'RVDJH'RVH5HJLPHQ3DWLHQWVZLOOEHUDQGRPL]H GLQDUDWLRWRRQHRI
WKHIROORZLQJJURXSVIRU%,'GRVLQJLQWKHVWXG\H\HLQWKHPRUQLQJDQGHYHQ LQJDSSUR[LPDWHO\KRXUV
DSDUWIRUGD\V
â€¢57$2SKWKDOPLF6XVSHQVLRQ
â€¢57$2SKWKDOPLF6XVSHQVLRQ
â€¢3ODFHERIRU57$2SKWK DOPLF6XVSHQVLRQ
6XPPDU\RI9LVLW6FKHGXOH9LVLW'D\Â•6FUHHQL QJ%DVHOLQH(YDOXDWLRQ
9LVLW'D\Â“KRXUVSRVWVXUJHU\6WXG\
HQUROOPHQW5DQGRPL]DWLRQDQGVW6WXG\
'UXJ'RVH
9LVLW'D\Â“2Q7UHDWPHQW)ROORZXS
,QIODPPDWLRQDQG3DLQ$VVHVVPHQWV
9LVLW'D\Â“2Q7UHDWPHQW)ROORZXS
,QIODPPDWLRQDQG3DLQ$VVHVVPHQWV
9LVLW'D\ ,QIODPPDWLRQDQG3DLQ
$VVHVVPHQWVDIWHU(QGRI7UHDWPHQW
9LVLW'D\Â“3RVW7UHDWPHQW)ROORZXS
([LW9LVLW
0HDVXUHV7DNHQWR5HGXFH%LDV5DQGRPL]DWLRQ ZLOO EH XVHG WR DYRLG ELDV LQ WKH
DVVLJQPHQWRISDWLHQWVWRWUHDWPHQWWRLQFUHDVHWKHOLNHOLKRRG WKDW NQRZQ DQG XQNQRZQ SDWLHQWDWWULEXWHV DUH HYHQO\ ED ODQFHG DFURVV WUHDWPHQW
JURXSV DQG WR HQKDQFH WKH YDOLGLW\ RI VWDWLVWLFDOFRPSDULVRQV DFURVV WUHDWPHQW JURXSV 0DVNHGWUHDWPHQW ZLOO EH XVHG WR UHGXFH SRWHQWLDO ELDVGXULQJ GDWD FROOHFWLRQ DQG HYDOXDWLRQ RI FOLQLFDOHQGSRLQWV
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 5 of 77 Study Population Characteristics  
Number of Patients : Approximately 105 patients will be enrolled in this 
study to complete 93 patient s: 31 per arm   
Condition/Disease:  Inflammation and pain following ocular surgery  
Inclusion Criteria:  Patient s must:  
1. Have provided written informed consent, 
approved by the appropriate institutional review board; 
2. Be able to comply with study requirements and visit schedule; 
3. Be greater than or equal to 18 years of age  of 
either sex or any race;  
4. Have undergone unilateral cataract extraction via 
phacoemulsification  and posterior chamber 
intraocular lens ( PCIOL ) implantation in the 
study eye on the day prior to study 
enrollment /randomization ; 
5. Have a grade of â‰¥  2 in a nterior chamber cell 
score on day after surgery (Day 1)  in the study 
eye; 
6. Have a po tential post- operative pin-hole visual 
acuity ( VA) < 1.0 logarithm of the minimum 
angle of resolution ( logMAR ) in the  operative 
eye and fellow eye as measured using an Early 
Treatment for Diabetic Retinopathy Study 
(ETDRS ) chart ; 
7. (For females of childbearing potential ) agree to 
have urine pregnancy testing performed at 
screening (must be negative) and at exit visit; 
must not be lactating; and must agree to use a medically acceptable form of birth control
1 
throughout the study duration. Women of 
childbearing potential include all females who 
have experienced menarche and have not 
experienced menopause (as defined by 
                                                 
1Acceptable forms of birth control are spermicide with barrier, oral contraceptive, injectable or implantable  
method of contraception, transdermal contraceptive, intrauterine device, or surgical sterilization of partner.  
For non -sexually active females, abstinence will be considered an acceptable form of birth control.  
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 6 of 77 amenorrhea for greater than 12 consecutive 
months) or have not undergone successful 
surgical sterilization (hysterectomy, bilateral 
tubal ligation, or bilater al oophorectomy).   
Exclusion Criteria:  Patient s must not: 
1. Have any intraocular inflammation present in the 
study eye during the screening slit lamp 
examination;  
2. Have a score greater than â€œ0â€ on the Ocular Pain 
Assessment at Screening  in the study eye; 
3. Have an immun osuppressive disease or an 
autoimmune disease that in the opinion of the 
Investigator could affect the quality of the ocular 
surface;  
4. Have active or chronic/recurrent ocular or 
systemic disease that is uncontrolled and will 
likely affect wound healing;  
5. Currently have suspected or known malignancy or is currently receiving antineoplastic therapy;  
6. Be a female who is currently pregnant, planning 
a pregnancy, lactating, not using a medically 
acceptable form of birth control throughout the study duration, or has a positive urine pregnancy test at screening ; 
7. Use anti -inflammatory agents , analgesics/pain 
relievers (including opioids, narcotics and other pain medications) or immunomodulating agents , 
systemically, or in the study eye , 
and/or use 
medications for benign prostatic hyperplasia 
(BPH) , from the washout period through the 
duration of the study. Washout periods for 
medications prior to surgery are as follows:  
a. Medications for BPH ( tamsulosin , silodosin, 
alfuzosin, finasteride): 28 days  
b. Systemic corticosteroids: 14 days 
c. Systemic analgesics/pain relievers (e.g. , 
gabapentin, pregabalin, NSAIDs and opioids): 14 days 
Note: Use of acetaminophen (up to 4,000 mg/day) and â€˜babyâ€™ aspirin (up to 81 mg/day) during the study are allowed. Use of an opioid during cataract surgery is 
allowed.  
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 7 of 77 d. Periocular injection of any corticosteroid 
solution: 28 days 
e. Corticosteroid depot in the study eye : 56 
days after implantation  
f. Cyclosporine: 56 days 
g. Topical ocular corticosteroid: 7 days  
h. Topical ocular NSAID : 7 days 
8. Have glaucoma or be taking medications to treat 
glaucoma in the study eye; 
9. Have an intraocular pressure ( IOP)  â‰¤ 5 mmHg  
in either eye ; 
10. Currently have or have a history of Herpes 
Simplex Keratitis  in the study eye ;  
11. Have active corneal abrasions or ulcers in the 
study eye;  
12. Have active or a history of chronic or recurrent 
inflammatory eye disease (e.g. iritis, scleritis, 
uveitis, iridocyclitis, rubeosis iritis) in the study 
eye; 
13. Have evidence of acute external ocular 
infections (bacterial, viral and/or fungal such as vaccinia, varicella, and other viral diseases of the cornea and conjunctiva);  tuberculosis of the eye; 
corneal dystrophies; intraocular infections, 
dysthyroid ophthalmopathy, active chalazion, or uncontrolled blepharitis in the study eye; 
14. Have uncontrolled and clinically significant dry 
eye syndrome in the study eye (artificial tears are allowed) ; 
15. Have proliferative diabetic retinopathy (PDR), 
compromised macular function; significant 
macular diseases; clinically significant macular edema (CS ME); or a history of cystoid macular 
edema in the study eye;  
16. Have had corneal or retinal surgery (laser or 
incisional) within the past 6 months, or be 
planning to have laser or incisional surgery 
during the study period in the study eye  (other 
than cataract surgery );  
17. Have surgery planned or scheduled for the 
contralateral eye during the study; 
18. Have previous ocular trauma with visible 
scarring or any deformities due to the trauma in the study eye;  
19. Require the use of a contact lens or a collagen 
shield with in 72 hours of investigational drug 
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 9 of 77 Efficacy Measures:  Hierarchical Primary Efficacy Measures  
1. a. Absence of anterior chamber cells (i.e., score 
of â€˜0â€™) at Visit 5 (Day 15) for the 1.0% 
concentration of RTA 408 Ophthalmic Suspension compared to Placebo  
 
b. Absence of anterior chamber cells (i.e., score of â€˜0â€™) at Visit 5 (Day 15) for the 0.5% 
concentration of RTA 408 Ophthalmic Suspension compared to Placebo  
 
2. a. Absence of pain (i.e., score of â€˜0â€™) at Visit 3 
(Day 4) for the 1.0% concentration of RTA 408 
Ophthalmic Suspension compared to Placebo  
 
b. Absence of pain (i.e., score of â€˜0â€™) at Visit 3 (Day 4) for the 0.5% concentration of RTA 408 
Ophthalmic Suspension compared to Placebo
 
Secondary Efficacy Measures  
1. Absence of anterior chamber cells at Visits 3, 4 
or 6 (Days 4, 8 or 21 respectively) 
2. Absence of pain at Visits  4, 5 or 6 (Days 8, 15 or 
21 respectively)  
3. Absence  of flare at Visits 3, 4, 5 or 6 (Days 4, 8, 
15 or 21 respectively) 
Safety Measures:  â€¢ Slit lamp biomicroscopy  
â€¢ Pin -hole visual acuity  
â€¢ IOP  
â€¢ Dilated indirect ophthalmoscopic examination   
â€¢ AE monitori ng  
Other:  None 
General Statistical  
Methods and Types  
of Analyses: 
 Efficacy Analysi s: 
Primary efficacy analyses will first test the 
difference in proportion of study eyes with a grade 
of â€˜0â€™ in anterior chamber cells between the 1.0% 
concentration of RTA 408 Ophthalmic Suspension 
and placebo  and between the 0.5% concentration of 
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 11 of 77 General Considerations:  
The unit of analysis in this study will be the study 
eye for all efficacy and safety summaries.  
Additionally, non- ocular adverse events will be 
presented at the patient  level. Non- study eye safety 
summaries will also be presented as appropriate.  
The primary analyses of all efficacy data will use 
last observation carried forward (LOCF) to impute missing data; data for visits after a patient  is 
discontinued for lack of efficacy will be imputed as 
failures for success/failure endpoints and will be 
imputed using LOCF for other endpoints. To check 
robustness of results, sensitivity analyses of the 
primary efficacy data will include analyses of 
observed data only, imputing data from patient  visits 
after discontinuation for lack of efficacy as failures.  
Other imputation methods may be applied as 
additional sensitivity analyses.  
Per protocol analyses will use observed data only, 
with the exception  of patient s who have missing data 
due to discontinuation for lack of efficacy; for these patient
s, missing data after discontinuation will be 
imputed as failures for success/failure endpoints and will be imputed using LOCF for other endpoints. 
Summaries f or continuous variables will include the 
sample size (n), mean, standard deviation, median, 
minimum, and maximum. Summaries for discrete 
variables will include frequencies and percentages. 
Differences between treatment groups will be 
calculated as Test â€“ Placebo  and change from 
baseline will be calculated as follow -up visit â€“ 
baseline. The baseline visit will be defined as the 
last non- missing measure prior to initiation of 
investigational treatment. All efficacy analyses wi ll 
use a one -sided alpha=0.10 tes t unless otherwise 
stated.  
The secondary efficacy variables, study eyes with absence of anterior chamber cells (Visits 3, 4 or 6), 
study eyes with absence of pain (Visits 4, 5  or 6) and 
study eyes with absence of flare (Visits 3, 4, 5 or 6) 
will be summarized similarly to the primary efficacy summaries. Additionally, anterior chamber cells and 
flare as well as pain at each visit and change from 
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 12 of 77 baseline will be summarized using continuous and 
discrete summary statistics.  
The sum of anterior chamber cells and flare grade 
will be summarized similarly to anterior chamber 
cells and flare separately.  
Safety Analysis: 
The primary safety analysis will summarize ocular 
treatment emergent AEs (TEAEs) in the study eye 
for all treated patient s using discrete summaries at 
the patient  and event level by system organ class and 
preferred term for each treatment group.  A TEAE 
will be defined as any AE that occurs after the 
treatment is initiated. An additional analysis will 
examine ocular AEs for the non -study eye. Non-
ocular TEAEs will be summarized using discrete 
summaries at the patient  and event level by system 
organ class and preferred term for each treatment group. Treatment related ocular and non-ocular TEAEs will be summarized similarly. Oc
ular and 
non-ocular TEAEs will also be summarized by 
severity.  
The IOP data will be summarized at each visit using both continuous summaries (including change from 
baseline) and discrete summaries (including the 
proportion of patient s with change in IOP fr om 
baseline â‰¥ 10 mm Hg and the proportion of patient s 
with an IOP â‰¥ 30 mm Hg that occurs at any time following initiation 
of study treatment) as well as 
shift tables.  
Slit lamp biomicroscopy and dilated indirect 
ophthalmoscopic exami nation measures will be  
summarized at each visit using discrete summary 
statistics.  
Visual Acuity data will be summarized at each visit, 
using discrete summaries including change from 
baseline in the number of lines and the proportion of patient s with worsening from previous vis it of â‰¥ 2 
lines.  
Summary of Known 
and Potential Risks and  This study is the first clinical study to evaluate the 
safety and efficacy of RTA 408  Ophthalmic 
Suspension. 
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 13 of 77 Benefits to Human Patient s 
 The ocular tolerability of RTA 408 was evaluated in 
multiple  nonclinical studies in rats, guinea pigs, 
rabbits, and monkeys. No ocular  or systemic toxicity 
was observed and systemic exposure was very low 
in all species tested.  Conjunctival irritation was 
observed in the rabbit ocular GLP toxicity study 
with frequen t dosing (4x/day); however, this was 
reversible, was not observed in a non- GLP study in 
rabbits, was not observed in the monkey ocular GLP 
toxicity study, and is readily monitorable in the 
clinic.  In vitro  and in vivo  studies conducted to date 
demonstrate that RTA 408 is a potent activator of 
the Nrf2 pathway and an inhibitor of the NF -ÎºB 
pathway, and should thus be an effective anti -
inflammatory agent for ophthalmic indications of 
inflammation and pain.  
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 14 of 77 TABLE OF CONTENTS  
SYNOPSIS  ..................................................................................................................................... 3  
List of Abbreviations .................................................................................................................. 17  
1 INTRODUCTION.............................................................................................................. 19  
2 STUDY OBJECTIVES  ...................................................................................................... 20  
3 CLINICAL HYPOTHESES  ............................................................................................. 20  
4 OVERALL STUDY DESIGN  ........................................................................................... 20  
5 STUDY POPULATION .................................................................................................... 21  
5.1 Number of Patients  .................................................................................................. 21  
5.2 Study Population Characteristics  .......................................................................... 21  
5.3 Inclusion Criteria  .................................................................................................... 21  
5.4 Exclusion Criteria  .................................................................................................... 22  
5.5 Withdrawal Criteria  ................................................................................................ 24  
6 STUDY PARAMETERS  ................................................................................................... 24  
6.1 Efficacy Measures  .................................................................................................... 24  
6.1.1  Secondary Efficacy Variables  ...................................................................... 24  
6.2 Safety Measures  ....................................................................................................... 24  
6.3 Other Measures  ....................................................................................................... 25  
7 STUDY MATERIALS  ....................................................................................................... 25  
7.1 Study Treatments  .................................................................................................... 25  
7.1.1  Study Treatments/Formulations  ................................................................... 25  
7.1.2  Instructions for Use and Administration ...................................................... 25  
7.2 Other Study Supplies  .............................................................................................. 25  
8 STUDY METHODS AND PROCEDURES  .................................................................... 26  
8.1 Patient Entry Procedures  ....................................................................................... 26  
8.1.1  Overview  ...................................................................................................... 26  
8.1.2  Informed Consent......................................................................................... 26  
8.1.3  Washout Intervals  ........................................................................................ 26  
8.1.4  Procedures for Final Study Entry ................................................................. 27  
8.1.5  Methods for Assignment to Treatment Groups ........................................... 27  
8.2 Concurrent Therapies  ............................................................................................. 27  
8.2.1  Prohibited Medications/Treatments  ............................................................. 27  
8.2.2  Escape Medications  ..................................................................................... 28  
8.2.3  Special Diet or Activities  ............................................................................. 29  
8.3 Examination Procedures ......................................................................................... 29  
8.3.1  Procedures to be Performed at Each Study Visit with Regard 
to Study Objectives ................................................................................................... 29  
8.4 Schedule of Visits, Measurements and Dosing  ..................................................... 32  
8.4.1  Scheduled Visits........................................................................................... 32  
8.4.2  Unscheduled Visits ...................................................................................... 32  
8.5 Compliance with Dosing  ......................................................................................... 33  
8.6 Patient Disposition  ................................................................................................... 33  
8.6.1  Completed Patients  ...................................................................................... 33  
8.6.2  Discontinued Patients................................................................................... 33  
8.7 Study Termination .................................................................................................. 34  
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 15 of 77 8.8 Study Duration ........................................................................................................ 34  
8.9 Monitoring and Quality Assurance  ....................................................................... 34  
9 ADVERSE EVENTS (AEs)  ............................................................................................... 35  
9.1 Adverse Event  .......................................................................................................... 35  
9.1.1  Severity  ........................................................................................................ 35  
9.1.2  Relationship to Study Drug .......................................................................... 35  
9.2 Serious Adverse Events (SAEs)  .............................................................................. 36  
9.3 Procedures for Reporting AEs  ............................................................................... 37  
9.3.1  Reporting a Suspected Unexpected Adverse Reaction  ................................ 37  
9.3.2  Reporting an SAE ........................................................................................ 37  
9.4 Procedures for Emergency Unmasking of Study Drug  ....................................... 38  
9.5 Type and Duration of the Follow- up of Patients after AEs  ................................. 38  
10 STATISTICAL HYPOTHESES AND METHODS OF ANALYSES ........................... 39  
10.1  Study P opulations .................................................................................................... 39  
10.1.1  Intent- to-Treat Population ............................................................................ 39  
10.1.2  Safety Population ......................................................................................... 39  
10.1.3  Per Protocol Population ............................................................................... 39  
10.2  Unit of Analysis ........................................................................................................ 39  
10.3  General Imputation Methods  ................................................................................. 39  
10.4  Efficacy Variables  .................................................................................................... 40  
10.5  Safety Variables ....................................................................................................... 40  
10.6  Statistical Hypotheses  .............................................................................................. 40  
10.7  Sample Size  .............................................................................................................. 42  
10.8  Methods  of Analyses ................................................................................................ 42  
10.9  Demographics and Baseline Medical History  ....................................................... 43  
10.10  Primary Efficacy Analyses  ..................................................................................... 43  
10.11  Secondary Efficacy Analyses .................................................................................. 44  
10.12  Safety Analyses ........................................................................................................ 44  
10.13  Subgroup Analysis  ................................................................................................... 44  
10.14  Interim Analysis  ...................................................................................................... 44  
11 COMPLIANCE WITH GOOD CLINICAL PRACTICES, ETHICAL 
CONSIDERATIONS, AND ADMINISTRATIVE ISSUES  ........................................... 45  
11.1  Protection of Human Subjects ................................................................................ 45  
11.1.1  Patient Informed Co nsent  ............................................................................ 45  
11.1.2  Institutional Review Board (IRB) Approval ................................................ 45  
11.2  Ethical Conduct of the Study  ................................................................................. 45  
11.3  Patient Confidentiality  ............................................................................................ 46  
11.4  Documentation ......................................................................................................... 46  
11.4.1  Retention of Documentation ........................................................................ 46  
11.5  Labeling, Packaging, Storage, Accountability, and Return or Disposal of Study Drug  ........................................................................................... 47
 
11.5.1  Labeling/Packaging ...................................................................................... 47  
11.5.2  Storage of Study Drug  ................................................................................. 47  
11.5.3  Accountability of Study Drug ...................................................................... 47  
11.5.4  Return or Disposal of Study Drug ............................................................... 47  
11.6  Recording of Data on Source Documents and eCRFs  .......................................... 47  
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 16 of 77 11.7  Handling of Biological Specimens  .......................................................................... 48  
11.8  Publications  .............................................................................................................. 48  
12 REFEREN CES  ................................................................................................................... 49  
APPENDIX 1: EXAMINATION PROCEDURES  .................................................................. 50  
APPENDIX 2:  SCHEDULE OF VISITS AND MEASUREMENTS  .................................... 56  
APPENDIX 3: PROTOCOL AMENDMENTS  ....................................................................... 57  
APPENDIX 4:  SPONSOR APPROVALS  ............................................................................... 76  
APPENDIX 5:  INVESTIGATORâ€™S SIGNATURE  ................................................................ 77  
 
  
57$2SKWKDOPLF6XVSHQVLR Q     5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO&     $PHQGPHQW)HE 

&RQILGHQWLDO  3DJHRI /LVWRI$EEUHYLDWLRQV
$( $GYHUVH(YHQW
$8& $UHDXQGHUWKHFXUYH%,' %LVLQGLHWZLFHGDLO\%3+ %HQLJQSURVWDWLFK\SHUSODVLD&)5 &RGHRI)HGHUDO5HJXODWLRQV&5) &DVH5HSRUW)RUP&52 &RQWUDFW5HVHDUFK2UJDQL]DWLRQ&60( &OLQLFDOO\VLJQLILFDQWPDFXODUHGHPD'++6 'HSDUWPHQWRI+HDOWKDQG+XPDQ6HUYLFHVH&5) (OHFWURQLF&DVH5HSRUW)RUP(7'56 (DUO\7UHDWPHQWRI' LDEHWLF5HWLQRSDWK\6WXG\
)'$ )RRGDQG'UXJ$GPLQLVWUDWLRQ*&3 *RRG&OLQLFDO3UDFWLFH+(& +\GUR[\HWK\OFHOOXORVH+,3$$ +HDOWK,QIRUPDWLRQ3RUWD ELOLW\DQG$FFRXQWDELOLW\$FW
+U +RXU,&) ,QIRUPHG&RQVHQW)RUP,&+ ,QWHUQDWLRQDO&RQIHUHQFHRQ+DUPRQLVDWLRQ,(& ,QGHSHQGHQW(WKLFV&RPPLWWHH,1' ,QYHVWLJDWLRQDO1HZ'UXJ$SSOLFDWLRQ
,1) â€¢ ,QWHUIHURQJDPPD
,23 ,QWUDRFXODU3UHVVXUH,5% ,QVWLWXWLRQDO,QGHSHQGHQW5HYLHZ%RDUG,77 ,QWHQWWR7UHDW/2&) /DVW2EVHUYDWLRQ&DUULHG)RUZDUGORJ0$5 /RJDULWKPRIWKH0LQLPXP$QJOHRI5HVROXWLRQP/ 0LOOLOLWHU
â€¢J 0LFURJUDP
1&6 1RWFOLQLFDOO\VLJQLILFDQW1'$ 1HZ'UXJ$SSOLFDWLRQ
1) â€¢â€¢ 1XFOHDUIDFWRUNDSSDOLJKWFKDLQH QKDQFHURIDFWLYDWHG%FHOOV
QJ 1DQRJUDP
12 1LWULFR[LGH14 1$'+TXLQLQHR[L GRUHGXFWDVH
1UI 1XFOHDUIDFWRUHU\WKURLGGHULYHG16$,' 1RQVWHURLGDODQWLLQIODPPDWRU\DJHQW3&,2/ 3RVWHULRUFKDPEHULQWUDRFXODUOHQV3'5 3UROLIHUDWLYHGL DEHWLFUHWLQRSDWK\
3+, 3URWHFWHG+HDOWK,QIRUPDWLRQ33 3HU3URWRFRO393 3RO\YLQ\OS\UUROLGRQH4' 4XDTXHGLH2QFHGDLO\
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 18 of 77 SAE  Serious Adverse Event  
SAP Statistical analysis plan  
SUN  Standardization of the Uveitis  Nomenclature  
VA Visual acuity  
  
57$2SKWKDOPLF6XVSHQVLR Q     5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO&     $PHQGPHQW)HE 

&RQILGHQWLDO  3DJHRI ,1752'8&7,21
)ROORZLQJRSKWKDOPLFVXUJHU\WKH FXUUHQWVWDQGDUGRIFDUHLQFO XGHVDWRSLFDORSKWKDOPLF
FRUWLFRVWHURLGRURWKHUDQWLLQIODPPDWRU\DJHQWWRWUHDWRFXODU LQIODPPDWLRQ DQGLPSURYH
SDWLHQWFRPIRUW,IOHIWXQWUHDWHGLQIODPPDWLRQRIWKHH\HPD\ UHVXOWLQIXUWKHURFXODU
FRPSOLFDWLRQVLQFOXGLQJVFDUULQJYLVLRQORVVRUEOLQGQHVV$O WKRXJKWKHH[DFWGRVLQJ
UHJLPHQLVSK\VLFLDQGHSHQGHQWSDWLHQWVDUHW\SLFDOO\SUHVFULE HGDWRSLFDOFRUWLFRVWHURLG
IRUDSHULRGRIZHHNVIROORZLQJVXUJHU\EHLQJWDSHUHGRYHU WKHFRXUVHRIGHOLYHU\DV
WKHLQIODPPDWLRQVXEVLGHV7RSLFDODQWLLQIODPPDWRU\DJHQWVDUH XVXDOO\DGPLQLVWHUHG
PXOWLSOHWLPHVSHUGD\SDUWLFXODUO\LQWKHHDUO\SHULRGIROORZ LQJRSKWKDOPLFVXUJHU\
&RQWLQXLQJ HIIRUWV LQ GUXJ GHYHORSPHQW DLP WR LGHQWLI\ DOWHUQDW LYHV WR RSKWKDOPLF
FRUWLFRVWHURLGXVHGXHWRWKH LUZHOONQRZQORFDODQGV\VWHPLF QHJDWLYHVLGHHIIHFWV
1DWXUDOWULWHUSHQRLGVVXFKDV ROHDQROLFDFLGDQGXUVROLFDFLG ZKLFKDUHGHULYHGIURP
SODQWH[WUDFWVKDYHEHHQXVHGH[WHQVLYHO\LQ$VLDQPHGLFLQHIR UWKHLUDQWLLQIODPPDWRU\
DQG DQWLFDQFHU SURSHUWLHV 5HIHUHQFH  /LX  $ VHULHV RI  VHPLV\QWKHWLF
WULWHUSHQRLGVZDVSUHSDUHGEDVHG RQWKHVWUXFWXUHRIROHDQROLF DFLGDQGWHVWHGWRLGHQWLI\
FRPSRXQGVRSWLPL]HGIRUWKHLUDELOLW\WRLQKLELWWKHLQGXFWLRQ RIQLWULFR[LGH12LQ
SULPDU\PRXVHPDFURSKDJHVWUHDWHGZLWKLQWHUIHURQJDPPD,)1 â€¢5HIHUHQFH +RQGD

57$LVDQRYHOROHDQDQHWULWH USHQRLGZLWKLQWKLVFODVVRIF RPSRXQGV7KHUHVXOWV
IURPLQYLWURDQGLQYLYRSUHFOLQLFDOVWXGLHVFRQGXFWHGW RGDWHGHPRQVWUDWHWKDW57$ 
DVZHOODVRWKHUVHPLV\QWKHWLFWULWHUSHQRLGVDUHSRWHQWDFWLY DWRUVRIWKH1UIQXFOHDU
IDFWRUHU\WKURLGGHULYHGSDWKZD\DQGLQKLELWRUVRIWKH1)È›% QXFOHDUIDFWRUNDSSD
OLJKWFKDLQHQKDQFHURIDFWLYDWHG %FHOOVSDWKZD\DQGWKXVLQ GXFHDQDQWLR[LGDQWDQG
DQWLLQIODPPDWRU\SKHQRW\SH
5HDWDKDVGHPRQVWUDWHGLQSUHF OLQLFDOPRGHOVWKDWWRSLFDORFXOD UDGPLQLVWUDWLRQRI57$
LQFUHDVHVWKHH[SUHVVLRQRI 142DSURWRW\SLFDO1UIWDUJH WJHQHLQWKHFRUQHDO
HSLWKHOLXPDQGWKHFRUQHDOHQGRWKH OLXPRIUDEELWVZLWKWKHJUH DWHVWHIIHFWREVHUYHGLQWKH
GRVHJURXS7RSLFDORFXODUDG PLQLVWUDWLRQRI57$[GD\ DWFRQFHQWUDWLRQVDV
ORZDVLVHIILFDFLRXV LQYLYRDVDQDQWLLQIODPPDWRU\DJHQWLQDUDEELWPRGHORI
SDUDFHQWHVLVLQGXFH GRFXODULQIODPPDWLRQ
57$  LV UHDGLO\ DEVRUEHG DQG GL VWULEXWHG LQWR RFXODU WLVVXHV  DIWHU WRSLFDO RFXODU
DGPLQLVWUDWLRQZLWKVXVWDLQHGF RQFHQWUDWLRQVREVHUYHGIRUDWO HDVWKRXUVDIWHUWKHODVW
GRVH7KLVRFXODUSKDUPDFRNLQHWLF SURILOHLVFRQVLVWHQWZLWKWK HHIILFDF\REVHUYHGZLWK
WZLFHGDLO\RFXODU GRVLQJLQUDEELWV
2FXODU*/3WR[LFLW\VWXGLHVKD YHEHHQFRPSOHWHGZLWK57$2S KWKDOPLF6XVSHQVLRQ
LQUDEELWVDQGPRQNH\VZLWKUHSHDWHG[GD\DGPLQLVWUDWLRQRI 57$
DQGIRUGD\V$VH[SHFWHGV\VWHPLFH[SRVXUHWR57$ ZDVYHU\ORZLQ
UDEELWVDQGPRQNH\VZLWKPD[LPXPFRQFHQWUDWLRQV& PD[RQ'D\RIDSSUR[LPDWHO\
DQGQJP/UHVSHFWLYHO\2YHUDOOWKHWRSLFDORFXODUD GPLQLVWUDWLRQRI57$
2SKWKDOPLF6XVSHQVLRQDWFRQFHQWU DWLRQVRIDQG IRXUWLPHVGDLO\IRU
GD\VLQUDEELWVEXWQRWPRQNH\VSURGXFHGRFXODULUULWDWLRQ EXWGLGQRWFDXVHDQ\
RFXODURUV\VWHPLFWR[LFLW\LQUDEELWVRUPRQNH\V7KXVWKHQ RREVHUYHGDGYHUVHHIIHFW
OHYHO 12$(/ ZDV GHWHUPLQHG WR EH DW OHDVW 57$ 2SKWKDOP LF 6XVSHQVLRQ
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 20 of 77 administered 4x/day for 28 days in rabbits and monkeys.  The conjunctival irritation 
observed in the rabbit ocular GLP toxicity study was reversible, was not observed in a non-GLP study in rabbits, was not observed in the monkey ocular GLP toxicity study, 
and is readily monitorable in the clinic. 
Although it is highly unlikely that meaningf ul systemic exposure will result following 
topical ocular administration in humans, the systemic toxicity potential of RTA  408 has 
been extensively investigated in rats and monkeys, with daily oral administration for up 
to 6 months in rats and 9 months in monkeys. 
Based on an integrated assessment of the nonclinical data, it is concluded that RTA 408 
has an acceptable safety profile for topical ophthalmic use as indicated in the proposed 
topical ocular study in patient s following uncomplicated cataract surg ery at 
concentrations of 0.5% and 1.0% with a BID dosage regimen .  
2 STUDY OBJECTIVES  
To evaluate the clinical efficacy and safety of RTA 408 Ophthalmic Suspension in two 
concentrations versus placebo in the treatment of patient s with inflammation and pain 
following uncomplicated cataract surgery . 
3 CLINICAL HYPOTHESES  
It is hypothesized that RTA 408 Ophthalmic Suspension will be more effective than 
placebo  in the alleviation of inflammation and pain following cataract surgery. 
4 OVERALL STUDY DESIGN 
This trial will be a  multi- center, double -masked, randomized, dose- ranging , placebo -
controlled study consisting of 6 visits over approximately 7 weeks ( 49 days). 
Randomization will be used to avoid bias in the assignment of patient s to treatment, to 
increase the likelihood that known and unknown patient  attributes (e.g., demographics 
and baseline characteristics) are evenly balanced across treatment groups, and to enhance the validity of statistical comparisons across treatment grou ps. Mask ed treatment will be 
used to reduce potential of bias during data collection and evaluation of clinical endpoints.    
At Visit 1  (Day -1 to Day -28), patient s will be screened to ensure that they meet all 
initial inclusion criteria and none of the exclusion criteria . Medical and medication 
histories will be taken,  the patient s will subjectively grade ocular pain using the scales 
provided, and pin- hole visual acuity will be assessed . The Investigator will then perform 
a slit lamp biomicroscop ic exami nation with intraocular pressure ( IOP) measurement , 
and grading of  anterior chamber inflammation . A dilated indirect ophthalmoscopic 
examination will also  be performed . Female patient s of childbearing potential will be 
given a urine pregnancy test.   
At Visit 2 (Day 1 , 24 Â± 6 hours post- surgery ), patient sâ€™ medical and medication histories 
will be updated, patient s will be queried for ocular pain, pin- hole visual acuity will be 
assessed, and the Investigator will perform a slit lamp biomicroscopic evaluation, IOP 
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 21 of 77 measurement, and grading of anterior chamber inflammation. Qualifying patient s  will 
then be randomized to one of the following treatment groups (in a 1:1:1  ratio): RTA 408 
Ophthalmic Suspension 0.5% (N= 35), RTA 408 Ophthalmic Suspension 1.0% (N =35), or 
placebo  for RTA 408 Ophthalmic Suspension (N=35). Study drug will be dispensed 
along with the Study Drug Compliance Diary.  A trained unmasked technician will 
instruct patient s on how to instill the study drug twice  daily in the morning and evening  
(approximately  12 hours apart ) for 14 days  on the eye that underwent surgery . The first 
dose of study drug will be instilled in -office.  
At Visits 3  (Day 4Â± 1 ), 4 (Day 8 Â± 1), and 5 ( Day 15 + 1), patient sâ€™ medical and 
medication histories will be updated, patient s will be queried for ocular pain, pin-hole 
visual acuity will be assessed, and  the Investigator  will perform a slit lamp 
biomicroscopic evaluation , IOP measurement , and grading of  anterior chamber 
inflammation.  AEs will be noted, and the Study Drug Compliance D iary will be 
reviewed. Day 14 will be the last day of study drug treatment at home . On Visit 5 ( Day 
15+ 1) , the study drug  and Study Drug Compliance D iary will be collected . 
At Visit 6 (Day 21 Â± 1), patient sâ€™ medical and medication histories will be updated, 
patient s will be queried for ocular pain, pin- hole visual acuity will be assessed, and the 
Investigator will perform a slit lamp biomicroscopic evaluation, IOP assessment, and 
gradin g of anterior chamber inflammation. A dilated indirect ophthalmoscopic 
examination will also be performed. AEs will be noted , and a urine pregnancy test will be 
given to females of childbearing potential. Patient s will then exit the study.  
5 STUDY POPULATION  
5.1 Number of Patients 
Approximately 105 patient s will be enrolled in this multi- center study , 35 per arm, in 
order to complete 31 patients per arm .  
5.2 Study Population Characteristics 
Patient s age 18 and older who are scheduled to undergo ocular surgery, and who 
meet all inclusion criteria and none of the exclusion criteria.  
5.3 Inclusion Criteria 
Each patient  must  meet the following criteria : 
1. Have provided written informed consent, approved by the appropriate institutional 
review board; 
2. Be able to comply with study requirements and visit schedule; 
3. Be greater than or equal to 18 years of age of either sex or any race;  
4. Have undergone unilateral cataract extraction via phacoemulsification and 
posterior chamber intraocular lens ( PCIOL ) implantation in the study eye  on the 
day prior to study enrollment/randomization; 
5. Have a grade of â‰¥  2 in anterior chamber cell score on day after surgery (Day 1)  in 
the study eye ; 
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 22 of 77 6. Have a potential post -operative pin- hole visual acuity (VA) < 1.0 logarithm  of the 
minimum angle of resolution (logMAR) in the operative eye and fellow eye as 
measured using an Early Treatment for Diabetic Retinopathy Study (ETDRS) chart;  
7. (For females of childbearing potential) agree to have urine pregnancy testing performed at s creening (must be negative) and at exit visit; must not be lactating; 
and must agree to use a medically acceptable form of birth control
2 throughout 
the study duration. Women of childbearing potential include all females who have 
experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy).   
5.4 Exclusion Criteria  
Each patient  may not meet any of the following: 
1. Have any intraocular inflammation present in the study eye during the screening slit lamp examination;  
2. Have a score greater than â€œ0â€ on the Ocular Pain Assessment at Screening in the study eye;  
3. Have an immunosuppressive disease or an autoimmune disease that in the opinion of the Investigator could affect the quality of the ocular surface; 
4. Have active or chronic/recurrent ocular or systemic disease that is uncontrolled and will likely affect wound healing; 
5. Currently have suspected or known malignancy or is currently receiving antineoplastic therapy;  
6. Be a female who is currently pregnant, planning a pregnancy, lactating, not using a medically acceptable form of birth control throughout the study duration, or has a positive uri ne pregnancy test at screening;  
7. Use anti -inflammatory  agents,  analgesics/pain relievers (including opioi ds, 
narcotics and other pain medications) or immunomodulating agents systemically, 
or in the study eye, and/or use medications  for benign prostatic hyperplasia 
(BPH),  from the washout period through the duration of the study. Washout 
periods for medications prior to surgery are as follows: 
a. Medications for BPH ( tamsulosin , silodosin, alfuzosin, finasteride): 28 days  
b. Systemic corticosteroids: 14 days  
c. Systemic analgesics/pain relievers (e.g. , gabapentin, pregabalin, NSAIDs and 
opioids): 14 days Note: Use of acetaminophen (up to 4,000 mg/day) and â€˜babyâ€™ aspirin (up to 81 mg/day) during the study are allowed. Use of an opioid during cataract surgery is al lowed. 
d. Periocular injection of any corticosteroid solution: 28 days 
                                                 
2Acceptable forms of birth control are spermicide with barrier, oral contraceptive, injectable or implantable  
method of contraception, transdermal contraceptive, intrauterine device, or surgical sterilization of partner.  
For non -sexually active females, abstinence will be considered an acceptable form of birth control.  
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 23 of 77 e. Corticosteroid depot in the study eye: 56 days after implantation  
f. Cyclosporine: 56 days 
g. Topical ocular corticosteroid: 7 days  
h. Topical ocular NSAID: 7 days 
8. Have glaucoma or be taking medi cations to treat glaucoma in the study eye;  
9. Have an intraocular pressure ( IOP)  â‰¤ 5 mmHg in either eye; 
10. Currently have or have a history of Herpes Simplex Keratitis in the study eye;  
11. Have active corneal abrasions or ulcers in the study eye;  
12. Have active or  a history of chronic or recurrent inflammatory eye disease (e.g. 
iritis, scleritis, uveitis, iridocyclitis, rubeosis iritis) in the study eye;  
13. Have evidence of acute external ocular infections (bacterial, viral and/or fungal 
such as vaccinia, varicella, and other viral diseases of the cornea and conjunctiva);  tuberculosis of the eye; corneal dystrophies; intraocular infections, dysthyroid ophthalmopathy, active chalazion, or uncontrolled blepharitis in the study eye; 
14. Have uncontrolled and clinically significant dry eye syndrome in the study eye (artificial tears are allowed);  
15. Have proliferative diabetic retinopathy (PDR), compromised macular function; significant macular diseases; clinically significant macular edema (CSME); or a history of cystoid macular edema in the study eye;  
16. Have had corneal or retinal surgery (laser or incisional) within the past 6 months, or be planning to have laser or incisional surgery during the study period in the study eye  (other than cataract surgery) ;  
17. Have  surgery planned or scheduled for the contralateral eye during the study;  
18. Have previous ocular trauma with visible scarring or any deformities due to the trauma in the study eye;  
19. Require the use of a contact lens or a collagen shield within 72 hours of investigational drug  treatment or during the study period in the study eye; be 
unwilling to discontinue use of contact lenses during study period in the study eye; 
20. Require use of non- diagnostic topical ophthalmic solutions (other than 
perioperative mydriatics, anesthetics and  antiseptics, prophylactic antibiotics, lid 
scrubs for mild blepharitis, or artificial tears for the management of dry eye) in the study eye for the duration of the study; 
21. Have known allergy or sensitivity to the investigational product or its components; 
22. Have ocular hemorrhage in the study eye that interferes with evaluation of post -
surgery inflammation;  
23. Have undergone any other ophthalmic surgical procedure (e .g., vitrectomy, 
relaxing incisions, iridectomy, conjunctival excisions, use of iris hooks or other iris dilators, etc.) in addition to the cataract extraction procedure and PCIOL 
implantation  in the study eye; 
24. Have previously enrolled in this clinical study, or are planning to participate in 
another clinical trial during the follow -up period, that could confound the 
treatment or outcomes of this investigation; 
25. Be excluded if the Investigator determines that the patient should not be included for reasons not already specified (e.g., systemic or other ocular 
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 24 of 77 disease/abnormality), if the health o f the patient or the validity of the study 
outcomes may be compromised by the patientâ€™s enrollment. 
5.5 Withdrawal Criteria  
If at any time during the study the investigator determines that a patient â€™s safety has 
been compromised, the patient  may be withdrawn from the study. 
Patient s may withdraw consent from the study at any time.  
Sponsor and/or investigator may discontinue any patient  for non- compliance or any 
valid medical reason (see Section 8.6.2). 
6 STUDY PARAMETERS  
6.1 Efficacy Measures  
The hierarchical prima ry efficacy variables are the following: 
1. Absence of anterior chamber cells (i.e., score of â€˜0â€™) at Visit 5 (Day 15) for:  
a. The 1.0% concentration of RTA 408 Ophthalmic Suspension compared 
to Placebo  
b. The 0.5% concentration of RTA 408 Ophthalmic Suspension compared 
to Placebo.  
2. Absence of pain (i.e., score of â€˜0â€™) at Visit 3 (Day 4) for:  
a. The 1.0% concentration of RTA 408 Ophthalmic Suspension compared to Placebo; to be tested if 1a. is statistically significant in favor of the active arm. 
b. The 0.5% concentration of RTA 408 Ophthalmic Suspension compared to Placebo; to be tested if 1b. is statistically significant in favor of the active arm. 
6.1.1 Secondary Efficacy Variables 
1. Absence of anterior chamber cells at Visits 3, 4, or 6 (Days 4Â±1, 8Â±1 , or 
21Â±1 , respectively)  
2. Absence of pain at Visits 4, 5 or 6 (Days 8 Â±1, 15+1 or 21Â±1 , respectively)  
3. Absence of flare at Visits 3, 4, 5 or 6 (Days 4Â±1, 8Â±1 , 15+1 or 21Â±1 , 
respectively)  
6.2 Safety Measures  
â€¢ Slit lamp biomicroscopy  
â€¢ Pin -hole visual acuity  
â€¢ IOP  
â€¢ Dilated indirect ophthalmoscopic examination  
â€¢ AE monitoring 
57$2SKWKDOPLF6XVSHQVLR Q     5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO&     $PHQGPHQW)HE 

&RQILGHQWLDO  3DJHRI 678'<0(7+2'6$1'352&('85(6
3DWLHQW(QWU\3URFHGXUHV
2YHUYLHZ
3DWLHQWV DV GHILQHG E\ WKH FU LWHULD LQ VHFWLRQ   DQG   ZLOO EH
FRQVLGHUHGIRUHQWU\LQWRWKLVVWXG\6HH$SSHQGL[IRUDWDEX ODUVXPPDU\RI
VWXG\YLVLWVDQGSURFHGXUHVUHTXLUHGIRUHDFKYLVLW
,QIRUPHG&RQVHQW
3ULRUWRDSDWLHQWÂ¶VSDUWLFLSDWL RQLQWKHWULDOLHFKDQJHV LQDSDWLHQWÂ¶VPHGLFDO
WUHDWPHQWDQGRUVWXG\UHODWHGSURFHGXUHVWKHVWXG\ZLOOEHG LVFXVVHGZLWK
HDFKSDWLHQWDQGSDWLHQWVZLVKLQJWRSDUWLFLSDWHPXVWJLYHZUL WWHQLQIRUPHG
FRQVHQWXVLQJDQLQIRUPHGFRQVHQ WIRUP7KHLQIRUPHGFRQVHQWI RUPPXVWEH
WKH PRVW UHFHQW YHUVLRQ WKDW KDV UHFHLYHG DSSURYDOIDYRUDEOH UH YLHZ E\ D
SURSHUO\FRQVWLWXWHG,QVWLWXWLRQDO5HYLHZ%RDUG
:DVKRXW,QWHUYDOV
6WXG\VWDIIZLOOFRQILUPWKDWWKHSDWLHQWKDVQRWXVHGSULRUWR 'D\IRUWKH
LQGLFDWHG ZDVKRXW LQWHUYDO DQ\ R I WKH IROORZLQJ GLVDOORZHG PHG LFDWLRQV
V\VWHPLFDOO\RULQWKHVWXG\H \HJURXSHGE\ZDVKRXWSHULRG
KRXUV
â€¢&RQWDFWOHQVRUDFROODJH QVKLHOGLQWKHVWXG\H\H
GD\V
â€¢7RSLFDORFXODUFRUWLFRVWHURLG
â€¢7RSLFDORFXODU16$,'
GD\V
â€¢6\VWHPLFFRUWLFRVWHURLGV
â€¢6\VWHPLF DQDOJHVLFVSDLQ UHOLHYH UV HJ JDEDSHQWLQ SUHJDEDOL Q
16$,'VDQGRSLRLGV
1RWH8VHRIDFHWDPLQRSKHQXSWRPJGD\DQGÂµEDE\Â¶DVSL ULQ
XSWRPJGD\GXULQJWKHVWXG\DUHDOORZHG8VHRIDQRSLRL G
GXULQJFDWDUDFWVXUJHU\LVDOORZHG
GD\V
â€¢3HULRFXODULQMHFWLRQRIDQ\ FRUWLFRVWHURLGVROXWLRQ
â€¢6\VWHPLF PHGLFDWLRQV IRU %3+ WD PVXORVLQ VLORGRVLQ DOIX]RVLQ 
ILQDVWHULGH
GD\V
â€¢&RUWLFRVWHURLGGHSRWLQWKHVWX G\H\HDIWHULPSODQWDWLRQ
57$2SKWKDOPLF6XVSHQVLR Q     5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO&     $PHQGPHQW)HE 

&RQILGHQWLDO  3DJHRI â€¢7RSLFDORFXODUF\FORVSRULQH
3URFHGXUHVIRU)LQDO6WXG\(QWU\
3DWLHQWVPXVWVDWLVI\DOOLQFOXVLRQDQGQRQHRIWKHH[FOXVLRQF ULWHULDLQRUGHUWR
EHHQWHUHGLQWRWKHVWXG\RQ6WXG\9LVLW
0HWKRGVIRU$VVLJQPHQW WR7UHDWPHQW*URXSV
$OOSDWLHQWVVFUHHQHGIRUWKHVWX G\ZKRVLJQDFRQVHQWIRUPZLO OEHDVVLJQHGD
GLJLW VFUHHQLQJ QXPEHU ZKLFK ZLOO EH HQWHUHG LQ WKH 6FUHHQLQJ  DQG
(QUROOPHQW/RJ7KH3DWLHQW,'QXPEHUZLOOEHDGLJLWQXPEHU FRQVLVWLQJRI
WKHGLJLWVLWHQXPEHUFRPELQH GZLWKWKHGLJLWVFUHHQLQJQXP EHU
2QFHDSDWLHQWPHHWVDOOTXDOLILFDWLRQFULWHULDWKH\ZLOOEHU DQGRPO\DVVLJQHG
WRPDVNHGWUHDWPHQWXVLQJD 57$57$ SODFHER
DVVLJQPHQWUDWLR3D WLHQWVZLOOEHUDQGRPL]HGRQWKHILUVWGD\ SRVWVXUJHU\
'D\E\DVVLJQPHQWRIWKHORZHVWGLJLWVWXG\GUXJNLWQXPE HUDYDLODEOHDW
WKHLULQYHVWLJDWLYHVLWH1RVWXG\GUXJNLWQXPEHUVZLOOEHVNL SSHGRURPLWWHG
$WUDLQHGXQPDVNHGWHFKQLFLDQZLOODGPLQLVWHUVWXG\GUXJIURP WKHERWWOHRI
WKHVWXG\GUXJNLWDVVLJQHGWRWKHSDWLHQW(DFKVWXG\GUXJNL WZLOOEHODEHOHG
ZLWKWKHGLJLWVWXG\GUXJNLWQXPEHU7KHERWWOHRIVWXG\GU XJZLOOEH
GLVSHQVHGWRWKHSDWLHQWI RUXVHRQVXEVHTXHQWGD\V
&RQFXUUHQW7KHUDSLHV
7KHXVHRIDQ\FRQFXUUHQWPHGLFDWLRQSUHVFULSWLRQRURYHUWKH FRXQWHUXVHGZLWKLQ
WKHODVWGD\VEHIRUH9LVLWDQGIRUWKHGXUDWLRQRIWKHVWX G\LVWREHUHFRUGHGRQ
WKHSDWLHQWÂ¶VVRXUFHGRFXPHQWD QGFRUUHVSRQGLQJFDVHUHSRUWIRU PH&5)DORQJ
ZLWKWKHUHDVRQWKHPHG LFDWLRQZDVWDNHQ
&RQFXUUHQW HQUROOPHQW LQ DQRWKHU LQYHVWLJDWLRQDO GUXJ RU GHYLFH  VWXG\ LV QRW
SHUPLWWHG
3URKLELWHG0HGLFD WLRQV7UHDWPHQWV
3URKLELWHGPHGLFDWLRQVWUHDWPHQWV IRUWKHGXUDWLRQRIWKHVWXG\ DUH
â€¢7RSLFDORFXODUFRUWLFRVWHURLGLQWKHVWXG\H\H
â€¢7RSLFDORFXODU16$,'LQWKHVWXG\H\H
â€¢6\VWHPLFFRUWLFRVWHURLGV
â€¢3HULRFXODULQMHFWLRQRIDQ\FRUWLF RVWHURLGVROXWLRQLQWKHVWXG \H\H
â€¢&RUWLFRVWHURLGGHSRWLQWKHVWX G\H\HDIWHULPSODQWDWLRQ
â€¢7RSLFDORFXODUF\FORVSRULQHLQWKHVWXG\H\H
â€¢$QWLLQIODPPDWRU\RULPPXQRPRGXODWLQJDJHQWVV\VWHPLFDOO\RUL Q
WKHVWXG\H\H
57$2SKWKDOPLF6XVSHQVLR Q     5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO&     $PHQGPHQW)HE 

&RQILGHQWLDO  3DJHRI â€¢6\VWHPLFPHGLFDWLRQVIRUEHQLJQSURVWDWLFK\SHUSODVLD%3+H J
WDPVXORVLQVLORGRVLQDOIX]RVLQILQDVWHULGH
â€¢6\VWHPLF$QDOJHVLFVSDLQUHOLHYH UVLQFOXGLQJRSLRLGVQDUFRWLF VDQG
RWKHU SDLQ PHGLFDWLRQV V\VWHPLFDO O\ HJ JDEDSHQWLQ SUHJDEDO LQ
16$,'VDQGRSLRLGV
1RWH8VHRIDFHWDPLQRSKHQXSWRPJGD\DQGÂµEDE\Â¶DVSL ULQ
XSWRPJGD\GXULQJWKHVWXG\DUHDOORZHG8VHRIDQRSLRL G
GXULQJFDWDUDFWVXUJHU\LVDOORZHG
â€¢*ODXFRPDPHGLFDWLRQVRURFXODUK \SHUWHQVLRQPHGLFDWLRQVLQWKH VWXG\
H\H
â€¢&RQWDFWOHQVRUDFROODJH QVKLHOGLQWKHVWXG\H\H
â€¢1RQGLDJQRVWLFWRSLFDORSKWKDOPLFVROXWLRQVRWKHUWKDQSHULRSH UDWLYH
P\GULDWLFV DQHVWKHWLFV DQG DQWLVHSWLFV SURSK\ODFWLF DQWLELRWL FV OLG
VFUXEVIRUPLOGEOHSKDULWLVRUD UWLILFLDOWHDUVIRUWKHPDQDJH PHQWRI
GU\H\HLQWKHVWXG\H\H
â€¢$QWLQHRSODVWLFWKHUDS\
â€¢$Q\RWKHURSKWKDOPLFVXUJLFDOSUR FHGXUHHJYLWUHFWRP\UHOD [LQJ
LQFLVLRQVLULGHFWRP\FRQMXQFWLYDOH[FLVLRQVXVHRILULVKRRN VRURWKHU
LULVGLODWRUVHWFLQDGGLWLRQWRWKHFDWDUDFWH[WUDFWLRQSUR FHGXUHDQG
3&,2/LPSODQWDWLRQLQWKHVWXG\H\H
â€¢3ODQWRKDYHODVHURULQFLVLRQDOVXUJHU\LQWKHVWXG\H\HRWKH UWKDQ
FDWDUDFWVXUJHU\

â€¢6XUJHU\SODQQHGRUVFKHGXOHGI RUWKHFRQWUDODWHUDOH\H

,IDSDWLHQWXVHVDGLVDOORZHG PHGLFDWLRQWKLVXVHZLOOEHUHF RUGHG DVD
SURWRFRO YLRODWLRQ 3URWRFRO YLR ODWLRQV PXVW EH UHSRUWHG WR WKH , 5 % L Q 
DFFRUGDQFHZLWKWKHLUVWDQGDUGRSHUDWLQJSURFHGXUHV
(VFDSH0HGLFDWLRQV
8VH RI HVFDSH PHGLFDWLRQV VKRXOG EH DYRLGHG LI SRVVLEOH ,I LQ WKH
LQYHVWLJDWRUÂ¶V DVVHVVPHQW HVFDSH PHGLFDWLRQ LV UHTXLUHG GXH WR ODFN RI
HIILFDF\WKHVWXG\GUXJVKRXOGEHGLVFRQWLQXHGSULRUWRDGPLQL VWUDWLRQRIWKH
ILUVWGRVHRIHVFDSHPHGLFDWLRQ7KHSDWLHQWVKRXOGUHPDLQLQ WKHVWXG\DQG
FRQWLQXH WR EH IROORZHG SHU WKH SURWRFRO IRU DOO UHPDLQLQJ YLVL WV DQG
DVVHVVPHQWV WR WKH HQG RI WKH V WXG\ 7KHVH SDWLHQWV ZKR UHTXLUH H V F D S H 
PHGLFDWLRQVKRXOGEHFRQVLGHUHG DVGLVFRQWLQXHGIURPVWXG\PHGL FDWLRQGXH
WRODFNRIHIILFDF\DQGWKHHVFDSHPHGLFDWLRQVXVHGPXVWEH GRFXPHQWHGLQ
WKHH&5)
57$2SKWKDOPLF6XVSHQVLR Q     5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO&     $PHQGPHQW)HE 

&RQILGHQWLDO  3DJHRI 6SHFLDO'LHWRU$FWLYLWLHV
1RWDSSOLFDEOH
([DPLQDWLRQ3URFHGXUHV
3URFHGXUHVWREH3HUIRUPHGDW(DFK6WXG\9LVLWZLWK5HJDUGWR6 WXG\
2EMHFWLYHV
9,6,76FUHHQLQJ9LVLW'D\WR'D\
â€¢,QIRUPHG&RQVHQW+,3$$ 3ULRUWRDQ\FKDQJHVLQDSDWLHQWÂ¶VPHGLFDO
WUHDWPHQW DQGRU SHUIRUPLQJ VWXG\ YLVLW SURFHGXUHV WKH VWXG\ Z LOO EH
GLVFXVVHGZLWKHDFKSDWLHQWDQGSDWLHQWVZLVKLQJWRSDUWLFLSDWH PXVWJLYH
ZULWWHQLQIRUPHGFRQVHQWD QGVLJQD+,3$$IRUP
â€¢5HYLHZRI,QFOXVLRQDQG([FOXVLRQ&ULWHULD ,ISDWLHQWVPHHWDOOLQLWLDO
LQFOXVLRQDQGQRQHRIWKHH[FOXVLRQF ULWHULDWKH\PD\FRPSOHWH WKLVYLVLW 
â€¢'HPRJUDSKLF GDWD DQG PHGLFDOP HGLFDWLRQRFXODU KLVWRU\ &R OOH F WD Q G 
UHFRUGDOOGHPRJUDSKLFGDWDPH GLFDOKLVWRU\DQ\PHGLFDWLRQV UHIHUWR
6HFWLRQ  DQG DQ\ XQGHUO\LQJ FRQGLWLRQV &XUUHQW XQGHUO\LQ J
FRQGLWLRQVLQFOXGLQJWKRVHWKDWEHJDQZLWKLQWKHODVWWKLUW\G D\VZKLFK
PD\KDYHEHHQUHVROYHGEHIRUHVFUHHQLQJPXVWEHUHFRUGHG5HFRU GDQ\
PHGLFDWLRQVWKHSDWLH QWLVWDNLQJDVZHOODVWKRVHWKHSDWLHQW PD\KDYH
WDNHQEXWGLVFRQWLQXHGZLWKLQ GD\VSULRUWRVFUHHQLQJUHIHU WR6HFWLRQ

â€¢8ULQH3UHJQDQF\7HVWIRUIHPDOH VRIFKLOGEHDULQJSRWHQWLDO :RPHQRI
FKLOGEHDULQJ SRWHQWLDO PXVW KDYH D QHJDWLYH XULQH SUHJQDQF\ WHV W WR
FRQWLQXH LQ WKH VWXG\ DQG PXVW DJUHH WR XVH DQ DGHTXDWH PHWKRG RI
FRQWUDFHSWLRQ IRU WKH GXUDWLRQ RI WKH VWXG\ LQ RUGHU WR EH HQUR OOHG
$FFHSWDEOH IRUPV RI ELUWK FRQWURO DUH VSHUPLFLGH ZLWK EDUULHU RUDO
FRQWUDFHSWLYH LQMHFWDEOH RU LPSODQWDEOH PHWKRG RI FRQWUDFHSWLR Q
WUDQVGHUPDOFRQWUDFHSWLYHLQWUDXWHULQHGHYLFHRUVXUJLFDOVWH ULOL]DWLRQRI
SDUWQHU
R)RUQRQVH[XDOO\DFWLYHIHPDOHV DEVWLQHQFHZLOOEHFRQVLGHUHG DQ
DFFHSWDEOHIRUPRIELUWKFRQWURO
â€¢$VVHVVPHQWRI2FXODU3DLQ 3DWLHQWVZLOODVVHVVRFXODUSDLQLQWKHVWXG\
H\HVHH$SSHQGL[ 
â€¢3LQ+ROH9LVXDO$FXLW\8WLOL]LQJDQ(7'56&KDUW 3DWLHQWVPXVWKDYHD
SRWHQWLDOSRVWRSHUDWLYHSLQKROH9$ORJ0$5LQWKHRSHUDW LYHH\H
DQGLQWKHIHOORZH\HDVPHDV XUHGXVLQJDQ(7'56FKDUW
â€¢6OLW/DPS%LRPLFURVFRS\ $VOLWODPSH[DPZLOOEHSHUIRUPHGLQERWK
H\HVWRH[FOXGHSDWLHQWVZLWKG LVDOORZHGRFXODUFRQGLWLRQVVHH $SSHQGL[

57$2SKWKDOPLF6XVSHQVLR Q     5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO&     $PHQGPHQW)HE 

&RQILGHQWLDO  3DJHRI â€¢$VVHVVPHQWRI2FXODU,QIODPPDWLRQ 7KH,QYHVWLJDWRUZLOODVVHVVDQWHULRU
FKDPEHUFHOOVDQGIODUHLQWKHVWXG\H\HXVLQJVOLWODPSELRPLF URVFRS\
VHH$SSHQGL[ 
â€¢$VVHVVPHQWRI,QWUDRFXODU3UHVVXUH 7RQRPHWU\ZLOOEHXVHGWRDVVHVV
LQWUDRFXODUSUHVVXUHLQERWKH\H V3DWLHQWVZKRKDYHRFXODUK\S RWHQVLRQ
,23Â” PP+J RU DUH WDNLQJ PHGLFDWLRQV WR WUHDW RFXODUK\SHUWHQVLRQJODXFRPDLQWKHVWX G\H\HZLOOEHH[FOXGHGIURPWK HVWXG\

â€¢'LODWHG ,QGLUHFW 2SKWKDOPRVFRSLF ([DPLQDWLRQ  'LODWHG LQGLUHFW
RSKWKDOPRVFRSLFH[DPLQDWLRQZLOOEH SHUIRUPHGLQERWKH\HVIRU VDIHW\
SXUSRVHVVHH$SSHQGL[
â€¢6FKHGXOHIRU9LVLW
9,6,7Â“+RXUV3RVW6XUJHU\'D\
â€¢8SGDWHRI0HGLFDO0HGLFDWLRQ+LVWRU\
â€¢$VVHVVPHQWRI2FXODU3DLQ
â€¢3LQ+ROH9LVXDO$FXLW\8WLOL]LQJDQ(7'56&KDUW
â€¢6OLW/DPS%LRPLFURVFRS\
â€¢$VVHVVPHQW RI 2FXODU ,QIODPPDWLRQ 2 Q O \ S D W L H Q W V Z L W K Â•  V F R U H L Q 
DQWHULRUFKDPEHUFHOOLQWKH VWXG\H\HZLOOEHLQFOXGHG
â€¢$VVHVVPHQWRI,QWUDRFXODU3UHVVXUH 3DWLHQWVZLOOEHH[FOXGHGZKRKDYHÂ”
PP+J,23RQWKHGD\DIWHUVXUJHU\LQHLWKHUH\H 
â€¢5HYLHZRI,QFOXVLRQDQG([FOXVLRQ&ULWHULD ,ISDWLHQWVPHHWDOOLQFOXVLRQ
DQGQRQHRIWKHH[FOXVLRQFULWHUL DWKH\ZLOOEHHQUROOHGLQWK HVWXG\DQG
UDQGRPL]HGWRUHFHLYHGUXJ 
â€¢5DQGRPL]DWLRQ 3DWLHQWVZKRPHHWDOOLQFOXVLRQDQGQRQHRIWKHH[FOXVLRQ
FULWHULDDQGTXDOLI\WRFRQWLQXHL QWKHVWXG\ZLOOEHUDQGRPL]H GWRPDVNHG
WUHDWPHQWUHIHUWR6HFWLRQ
â€¢6WXG\'UXJ,QVWLOODWLRQ $WUDLQHGXQPDVNHGWHFKQLFLDQQRWLQYROYHGLQ
DQ\RWKHUVWXG\DVVHVVPHQWVZLOOLQVWUXFWWKHSDWLHQWWRSHUIRU PVWXG\GUXJ
LQVWLOODWLRQRIRQHH\HGURSWRWKHVWXG\H\H7KHILUVWGRVHL QVWLOOHGGXULQJ
WKLVYLVLWZLOOEHFRQVLGHUHGWKHPRUQLQJGRVHUHJDUGOHVVRIWK HWLPHLQ
ZKLFKLWLVLQVWLOOHG7KHVHF RQGGRVHZLOOEHLQVWLOOHGLQWKH HYHQLQJDQG
PD\EHLQVWLOOHGOHVVWKD QDSSUR[LPDWHO\KRXUVDSDUW 
â€¢6WXG\ 'UXJ DQG 6WXG\ 'UXJ &RPSOLDQFH 'LDU\ 'LVSHQVDWLRQ DQG
,QVWUXFWLRQV $WUDLQHGWHFKQLFLDQZLOOLQVWUXFWSDWLHQWVRQKRZWRLQVWLO O
WKHVWXG\GUXJUHIHUWR6HFWL RQDQGFRPSOHWHWKHSDWLHQ WGLDU\DW
KRPH7KHVWXG\GUXJDQGVWXG\GUXJFRPSOLDQFHGLDU\ZLOOEHGL VSHQVHG
WRSDWLHQWVIRUKRPHXVH 
57$2SKWKDOPLF6XVSHQVLR Q     5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO&     $PHQGPHQW)HE 

&RQILGHQWLDO  3DJHRI â€¢$(4XHU\ $(VERWKHOLFLWHGDQGREVHUYH GZLOOEHPRQLWRUHGWKURXJKRXW
WKHVWXG\$OO$(VERWKHOLFLWHGDQGREVHUYHGZLOOEHSURPSW O\UHYLHZHG
E\ WKH ,QYHVWLJDWRU IRU DFFXUDF\ DQG FRPSOHWHQHVV $OO $(V ZLOO E H 
GRFXPHQWHGRQWKHDSS URSULDWHH&5)
â€¢6FKHGXOHIRU9LVLW
9,6,7'D\Â“
â€¢8SGDWHRI0HGLFDO0HGLFDWLRQ+LVWRU\
â€¢5HYLHZRI6WXG\'UXJ& RPSOLDQFH'LDU\
â€¢$VVHVVPHQWRI2FXODU3DLQ
â€¢3LQ+ROH9LVXDO$FXLW\8WLOL]LQJDQ(7'56&KDUW
â€¢6OLW/DPS%LRPLFURVFRS\
â€¢$VVHVVPHQWRI2FXODU,QIODPPDWLRQ 
â€¢$VVHVVPHQWRI,QWU DRFXODU3UHVVXUH
â€¢$(4XHU\
â€¢6FKHGXOHIRU9LVLW
9,6,7'D\Â“
â€¢8SGDWHRI0HGLFDO0HGLFDWLRQ+LVWRU\
â€¢5HYLHZRI6WXG\'UXJ& RPSOLDQFH'LDU\
â€¢$VVHVVPHQWRI2FXODU3DLQ
â€¢3LQ+ROH9LVXDO$FXLW\8WLOL]LQJDQ(7'56&KDUW
â€¢6OLW/DPS%LRPLFURVFRS\
â€¢$VVHVVPHQWRI2FXODU,QIODPPDWLRQ 
â€¢$VVHVVPHQWRI,QWU DRFXODU3UHVVXUH
â€¢$(4XHU\
â€¢6FKHGXOHIRU9LVLW
9,6,7'D\
â€¢8SGDWHRI0HGLFDO0HGLFDWLRQ+LVWRU\
â€¢5HYLHZRI6WXG\'UXJ& RPSOLDQFH'LDU\
â€¢&ROOHFWLRQRI6WXG\'UXJDQG6WXG\' UXJ&RPSOLDQFH'LDU\
â€¢$VVHVVPHQWRI2FXODU3DLQ
â€¢3LQ+ROH9LVXDO$FXLW\8WLOL]LQJDQ(7'56&KDUW
57$2SKWKDOPLF6XVSHQVLR Q     5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO&     $PHQGPHQW)HE 

&RQILGHQWLDO  3DJHRI â€¢6OLW/DPS%LRPLFURVFRS\
â€¢$VVHVVPHQWRI2FXODU,QIODPPDWLRQ 
â€¢$VVHVVPHQWRI,QWU DRFXODU3UHVVXUH
â€¢$(4XHU\
â€¢6FKHGXOHIRU9LVLW
9,6,7(;,79,6,7'D\Â“RU(DUO\([LW
â€¢8SGDWHRI0HGLFDO0HGLFDWLRQ+LVWRU\
â€¢5HYLHZRI6WXG\'UXJ& RPSOLDQFH'LDU\
â€¢&ROOHFWLRQRI6WXG\'UXJDQG6WXG\ 'UXJ&RPSOLDQFH'LDU\
â€¢$VVHVVPHQWRI2FXODU3DLQ
â€¢3LQ+ROH9LVXDO$FXLW\8WLOL]LQJDQ(7'56&KDUW
â€¢6OLW/DPS%LRPLFURVFRS\
â€¢$VVHVVPHQWRI2FXODU,QIODPPDWLRQ 
â€¢$VVHVVPHQWRI,QWU DRFXODU3UHVVXUH
â€¢'LODWHG,QGLUHFW2SKWKDOPRVFRSLF([DPLQDWLRQ
â€¢$(4XHU\
â€¢8ULQH3UHJQDQF\7HVWIRU:RPHQRI&KLOGEHDULQJ3RWHQWLDO
â€¢([LW3DWLHQWVZLOOH[LWWKHVWXG\ 
6FKHGXOHRI9LVLWV0HDVXUHPHQWVDQG'RVLQJ
6FKHGXOHG9LVLWV
5HIHUWR$SSHQGL[IRUDVFKH GXOHRIYLVLWVDQGPHDVXUHPHQWV
8QVFKHGXOHG9LVLWV
7KHVH YLVLWV PD\ EH SHUIRUPHG LQ RUGHU WR HQVXUH SDWLHQW VDIHW\  $OO
LQIRUPDWLRQ JDWKHUHG DW XQVFKHGXOHG YLVLWV VKRXOG EH UHFRUGHG R Q WKH
8QVFKHGXOHG9LVLWSDJHVRIWKH 6RXUFH'RFXPHQWDQGFRUUHVSRQGLQ JH&5)
,IDUDQGRPL]HGSDWLHQWGRHVQRW DWWHQGWKHLUVFKHGXOHGYLVLW WKHH&5)SDJHV
IRUWKHPLVVHGYLVLWZLOOEHVNLSSHG

7KHVHSURFHGXUHVDUHWREHFRPSOHWHGRQ9LVLWRQO\LIQRWSH UIRUPHGDW9LVLW
57$2SKWKDOPLF6XVSHQVLR Q     5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO&     $PHQGPHQW)HE 

&RQILGHQWLDO  3DJHRI $OOHIIRUWVVKRXOGEHPDGHWRVFKHGXOHSDWLHQWVIRUDQ([LW9LV LWWRFRPSOHWH
([LW3URFHGXUHV,QIRUPDWLRQIURP(DUO\([LW9LVLWVVKRXOGEHU HFRUGHGRQWKH
9LVLW([LW9LVLWSDJHV
(YDOXDWLRQVWKDWPD\EHFRQGXFWHG DWDQ8QVFKHGXOHG9LVLWDVD SSURSULDWH
GHSHQGLQJRQWKHUHDVRQIR UWKHYLVLWLQFOXGH
â€¢8SGDWH0HGLFDO0HGLFDWLRQ+LVWRU\
â€¢5HYLHZ&ROOHFW6WXG\'UXJ&RPSOLDQFH'LDU\DQG6WXG\'UXJ
â€¢$VVHVVPHQWRIRFXODUSDLQ
â€¢3LQKROHYLVXDODFXLW\
â€¢6OLWODPSELRPLFURVFRS\
â€¢$VVHVVPHQWRI2FXODU,QIODPPDWLRQ
â€¢,QWUDRFXODUSUHVVXUHPHDVXUHPHQW
â€¢'LODWHGLQGLUHFWRSKWKDOP RVFRSLFH[DPLQDWLRQ
â€¢$VVHVVPHQWRI$(V
â€¢8ULQHSUHJQDQF\WHVWIRUIHPDOHVRIFKLOGEHDULQJSRWHQWLDO
&RPSOLDQFHZLWK'RVLQJ
6LWHVWDIIZLOOUHYLHZFRQFRPLWD QWPHGLFDWLRQXV HDWHDFKYLVLW 
3DWLHQWVZLOOEHSURYLGHGZLWKDVWXG\GUXJFRPSOLDQFHGLDU\WR GRFXPHQW%,'
GRVLQJIRUGD\V3DWLHQWFRPSOLDQFHZLWKGRVLQJZLOOEHDVVH VVHGE\LQRIILFH
UHYLHZRIVWXG\GUXJFRPSOLDQFHGLDU\3DWLHQWVZKRPLVVPRUHW KDQRIWKHLU
VWXG\GUXJGRVHV PRUHWKDQ WRWDOGRVHVZLOOEHFRQVLGHUHGQRQFRPSOLDQWZLWK
GRVLQJDQGDSURWRFROGH YLDWLRQVKRXOGEHUHFRUGHG
3DWLHQW'LVSRVLWLRQ
&RPSOHWHG3DWLHQWV
$FRPSOHWHGSDWLHQWLVRQHZKRKDVQRWEHHQGLVFRQWLQXHGIURPW KHVWXG\DQG
FRQWLQXHVVWXG\DVVHVVPHQWVWKURXJK9LVLW'D\
'LVFRQWLQXHG3DWLHQWV
3DWLHQWVPD\EHGLVFRQWLQXHGIURPWKHVWXG\SULRUWRWKHLUFRP SOHWLRQRIWKH
VWXG\GXHWRDQ\RIWKHIROORZLQJUHDVRQV
â€¢$(V
â€¢3URWRFROYLRODWLRQV
â€¢/DFNRIHIILFDF\
â€¢$GPLQLVWUDWLYHUHDVRQVHJLQDELOLW\WRFRQWLQXHORVWWRIR OORZXS
57$2SKWKDOPLF6XVSHQVLR Q     5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO&     $PHQGPHQW)HE 

&RQILGHQWLDO  3DJHRI â€¢6SRQVRUWHUPLQDWLRQRIVWXG\
â€¢9ROXQWDU\ZLWKGUDZDO
â€¢3UHJQDQF\
,I D IHPDOH KDV D SRVLWLYH SUHJQDQF\ WHVW GXULQJ WKH VWXG\ WKH 
SDWLHQWVKRXOGVWRSVWXG\WUHDWPH QWDQGWKH,QYHVWLJDWRUZLOO QRWLI\
WKHVSRQVRULPPHGLDWHO\7KH,QYH VWLJDWRUVKDOOUHTXHVWFRSLHV RIDOO
UHODWHGPHGLFDOUHSRUWVGXULQJWK HSUHJQDQF\DQGVKDOOGRFXPHQW 
WKH RXWFRPH RI WKH SUHJQDQF\ IURP  WKH SDWLHQW DQGRU SDWLHQWÂ¶V
SK\VLFLDQ7KH,QYHVWLJDWRUZLOOUHWDLQWKHVHUHSRUWVWRJHWKHU ZLWK
WKH SDWLHQWÂ¶V VRXUFH GRFXPHQWV DQG ZLOO SURYLGH D FRS\ RI DOOGRFXPHQWDWLRQWRWKHVSRQVRU
â€¢2WKHU
1RWH,QDGGLWLRQDQ\SDWLHQWPD\EHGLVFRQWLQXHGIRUDQ\VRXQ GPHGLFDO
UHDVRQ
1RWLILFDWLRQRIDSD WLHQWÂ¶VGLVFRQWLQXDWLRQRIVWXG\GUXJDGPLQ LVWUDWLRQDQGWKH
UHDVRQIRUGLVFRQWLQXDWLRQZLOOEHPDGHWR&52DQGVWXG\6SRQVR UDQGZLOO
EHFOHDUO\GRFXPHQWHGRQWKHH&5)3DWLHQWVZKRUHFHLYHHVFDSH PHGLFDWLRQ
DUHWRGLVFRQWLQXHVWXG\GUXJDG PLQLVWUDWLRQDQGDUHWRUHPDLQ LQWKHVWXG\DQG
EHIROORZHGSHUWKHSURWRFROWR WKHHQGRIWKHVWXG\3DWLHQWV ZKRGLVFRQWLQXH
VWXG\GUXJDGPLQLVWUDWLRQIRURW KHUUHDVRQVDUHHQFRXUDJHGWRU HPDLQLQWKH
VWXG\DQGFRQWLQXHZLWKVWXG\D VVHVVPHQWVWKURXJKWKHHQGRIWK HVWXG\
1RWLILFDWLRQ RI D SDWLHQWÂ¶V GLVFRQWLQXDWLRQ RI VWXG\ SDUWLFLSDW LRQ DQG WKH
UHDVRQIRUGLVFRQWLQXDWLRQZLOOEHPDGHWR&52DQGVWXG\6SRQVR UDQGZLOO
EHFOHDUO\GRFXPH QWHGRQWKHH&5)
6WXG\7HUPLQDWLRQ
7KHVWXG\PD\EHVWRSSHGDWDQ\WLPHE\WKH,QYHVWLJDWRURUWKH 6SRQVRUZLWK
DSSURSULDWHQR WLILFDWLRQ
6WXG\'XUDWLRQ
$QLQGLYLGXDOSDWLHQWÂ¶VSDUWLFLSD WLRQLQWKHVWXG\LVH[SHFWHG WRODVWDSSUR[LPDWHO\
ZHHNVIURPVFUHHQLQJWRH[LW
0RQLWRULQJDQG4XDOLW\$VVXUDQFH
'XULQJWKHFRXUVHRIWKHVWXG\D&52PRQLWRURUGHVLJQHHZLOO PDNHURXWLQHVLWH
YLVLWVWRUHYLHZSURWRFROFRPSOLDQFHDVVHVVVWXG\GUXJGHYLFH DFFRXQWDELOLW\DQG
HQVXUH WKH VWXG\ LV EHLQJ FRQGXFWHG DFFRUGLQJ WR WKH SHUWLQHQW UHJXODWRU\
UHTXLUHPHQWV7KHUHYLHZRIWKHSDWLHQWVÂ¶PHGLFDOUHFRUGVZLOO EHSHUIRUPHGLQD
PDQQHUWKDWDGHTXDWHO\PDLQWDLQV SDWLHQWFRQILGHQWLDOLW\)XUWK HUGHWDLOVRIWKHVWXG\
PRQLWRULQJZLOOEHRXWOLQHGLQDPRQLWRULQJSODQ
5HJXODWRU\DXWKRULWLHVRIGRPHVWLFDQGIRUHLJQDJHQFLHVWKH6S RQVRUDQGRULWV
GHVLJQHHVPD\FDUU\RXWRQVLWHLQVSHFWLRQVDQGRUDXGLWVZKLFK PD\LQFOXGHVRXUFH
57$2SKWKDOPLF6XVSHQVLR Q     5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO&     $PHQGPHQW)HE 

&RQILGHQWLDO  3DJHRI GDWDFKHFNV7KHUHIRUHGLUHFWDFFHVVWRWKHRULJLQDOVRXUFHGDW DZLOOEHUHTXLUHGIRU
LQVSHFWLRQV DQGRU DXGLWV $OO LQVSHFWLRQV DQG DXGLWV ZLOO EH F DUULHG RXW JLYLQJ
FRQVLGHUDWLRQWRGDWDSURWHFWLRQDVZHOODVSDWLHQWFRQILGHQWLD OLW\WRWKHH[WHQWWKDW
ORFDOVWDWHDQGIHGHUDOODZVDSSO\
$'9(56((9(176$(V
$GYHUVH(YHQW
$Q$(LVGHILQHGDVDQ\XQWRZDUGPHGLFDORFFXUUHQFHDVVRFLDWHG ZLWKWKHXVHRID
GUXJLQKXPDQVZKHWKHURUQRWWKHHYHQWLVFRQVLGHUHGGUXJUHO DWHG$Q$(FDQ
WKHUHIRUH EH DQ\ XQIDYRUDEOH DQG XQLQWHQGHG VLJQ HJ DQ DEQR UPDO ODERUDWRU\
ILQGLQJV\PSWRPRUGLVHDVHR FFXUULQJDIWHUWKHILUVWGRVHRI VWXG\GUXJZLWKRXW
DQ\MXGJPHQWDERXWFDXVDOLW\$Q\SUHH[LVWLQJPHGLFDOFRQGLWLR QWKDWZRUVHQVDIWHU
ILUVWDGPLQLVWUDWLRQRIWKHVWXG\GUXJZLOODOVREHFRQVLGHUHG DQHZ$(7KH$(
UHSRUWLQJSHULRGHQGVXSRQVWXG\H[LW6WXG\GUXJLQFOXGHVWKH LQYHVWLJDWLRQDOGUXJ
XQGHUHYDOXDWLRQDQGSODFHERJLYHQGXU LQJDQ\VWDJHRIWKHVWXG \
'RFXPHQWDWLRQUHJDUGLQJWKH$(VKRXOGEHPDGHDVWRWKHQDWXUH GDWHRIRQVHWHQG
GDWHVHYHULW\UHODWL RQVKLSWRVWXG\GUXJDFWLRQVWDNHQVH ULRXVQHVVDQGRXWFRPH
RIDQ\VLJQRUV\PSWRPREVHUYHGE\WKHSK\VLFLDQRUUHSRUWHGE\ WKHSDWLHQWXSRQ
LQGLUHFWTXHVWLRQLQJ
6HYHULW\
6HYHULW\RIDQ$(LVGHILQHGDVDTXDOLWDWLYHDVVHVVPHQWRIWKH GHJUHHRI
LQWHQVLW\RIDQ$(DVGHWHUPLQHGE\WKH,QYHVWLJDWRURUUHSRUWH GWRKLPKHUE\
WKHSDWLHQW7KHDVVHVVPHQWRIVHYHULW\LVPDGHLUUHVSHFWLYHRI UHODWLRQVKLSWR
VWXG\GUXJRUVHULRXVQHVVRIWKHHYHQWDQGVKRXOGEHHYDOXDWHG DFFRUGLQJWR
WKHIROORZLQJVFDOH
â€¢0LOG(YHQWLVQRWLFHDEOHWRWKHSDWLHQWEXWLVHDVLO\WROHUDWHG DQGGRHV
QRWLQWHUIHUHZLWKWKHSDWLHQWÂ¶VGDLO\DFWLYLWLHV
â€¢0RGHUDWH (YHQWLVERWKHUVRPHSRVVLEO \UHTXLULQJDGGLWLRQDOWKHUDS\
DQGPD\LQWHUIHUHZLWKWKH SDWLHQWÂ¶VGDLO \DFWLYLWLHV
â€¢6HYHUH(YHQWLVLQWROHUDEOHQHFHVVLWDWHVDGGLWLRQDOWKHUDS\RUDOW HUDWLRQ
RIWKHUDS\DQGLQWHUIHUHVZ LWKWKHSDWLHQWÂ¶V GDLO\DFWLYLWLHV 
5HODWLRQVKLSWR6WXG\'UXJ
7KHUHODWLRQVKLSRIHDFK$(WRWKHVWXG\GUXJVKRXOGEHGHWHUPL QHGE\WKH
,QYHVWLJDWRUXVLQJWKHVHH[SODQDWLRQV
â€¢6XVSHFWHG $UHDVRQDEOHSRVVLELOLW\H[LVWVWKDWWKHVWXG\GUXJFDXVHG
WKH$(
â€¢1RW6XVSHFWHG $UHDVRQDEOHSRVVLELOLW\GRHVQRWH[LVWWKDWWKHVWXG\
GUXJFDXVHGWKH$(
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 36 of 77 Suspected adverse reaction means any AE for which there is a reasonable 
possibility that the study drug caused the AE. â€œReasonable possibility â€ means 
there is evidence to suggest a causal relationship between the stu dy drug and 
the AE.  Types of evidence that would suggest a causal relationship between 
the study drug  and the AE include: the event follows a reasonable temporal 
sequence from the time of study drug administration, and/or, follows a known 
response pattern to the study drug, but could have been produced by other factors; a reasonable temporal sequence of the event with study drug administration e xists and, based upon the known pharmacologic action of the 
drug, known or previously reported adverse reactions to the drug or class of drugs, or judgment based on the investigatorâ€™s clinical experience, the association of the event  with study drug administration seems likely; a single 
occurrence of an event that is uncommon and known to be strongly associated with drug exposure ( e.g., angioedema, hepatic injury, Stevens -Johnson 
Syndrome); one or more occurrences of an event that is not commonly associated  with drug exposure, but is otherwise uncommon in the population 
exposed to the drug ( e.g., tendon rupture);  an aggregate analysis of specific 
events observed in a clinical trial (such as known consequences of the underlying disease or condition under investigation or other events that commonly occur in the study population independent of drug therapy) that indicates those events occur more frequently in the drug treatment group than in a concurrent or historical control group. 
9.2 Serious Adverse Events (SAEs) 
An AE  is considered serious if, in the view of either the Investigator or Sponsor , it 
results in any of the following regulatory outcome definition s: 
1. Death ; 
2. A life -threatening AE; 
ï‚§ Note:  An AE  is considered â€œli fe-threateningâ€ if, in the view  of either 
the Investigator or Sponsor , its occurrence places the patient or patient  
at immediate risk of death. It does not include an AE that, had it 
occurred in a more severe form, might have caused death. 
3. Inpatient hospitalization or prolongation of existing hospitalization ; 
ï‚§ Note:  The term â€œinpatient hospitalizationâ€ refers to any inpatient admission  (even if less than 24 hours). For chronic or long -term 
inpatients, inpatient admission includes transfer within the hospital to an acute/ intensive care inpatient unit. Inpatient hospitalization does not 
include: emergency room visits; outpatient/same -day/ambulatory 
procedures; observation/short stay units; rehabilitation facilities; hospice facilities; nursing homes; or clinical research/P hase 1 units. 
ï‚§ Note:  The term â€œprolongation of existing hospitalizationâ€ refers to any 
extension of an inpatient hospitalization beyond the stay anticipated or 
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 37 of 77 required for the reason for the initial admission as determined by the 
Investigator or treating physician.  
4. A per sistent or significant incapacity or substantial disruption of the ability 
to conduct normal life functions; 
ï‚§ Note: An SAE  specifically related to visual threat would be interpreted 
as any potential impairment or damage to the patient â€™s eyes ( e.g., 
hemorrha ge, retinal detachment, central corneal ulcer or damage to the 
optic nerve). 
5. A congenital anomaly/birth defect ; 
6. Import ant medical event.  
ï‚§ Note: Important medical events  that may not result in death, ar e life -
threatening, or require hospitalization may be co nsidered serious 
when, based upon appropriate medical judgment, they may jeopardize 
the patient or patient  and may require medical or surgical intervention 
to prevent one of the outcomes listed in this definition. 
9.3 Procedures for Reporting AEs 
All AEs and their outcomes must be reported to the study Sponsor or designee , and 
the IRB/IEC as required by the IRB/IEC, federal, state , or local regulations and 
governing health authorities and recorded on the appropriate eCRF . AEs should be 
reported from the fi rst instillation of study drug until the final study visit.  
9.3.1 Reporting a Suspected U nexpected Adverse Reaction  
All AEs that are â€˜suspectedâ€™ and â€˜unexpectedâ€™ are to be reported to CRO , the 
study Sponsor and the IRB/IEC as required by the IRB/IEC, federal, state, or 
local  regulations and governing health authorities. 
9.3.2 Reporting an SAE  
To ensure patient  safety, all SAE s, regardless of relationship to the study drug, 
must be immediately reported (i.e. no later than 24 hours after the siteâ€™s 
awareness of the event) .  All information relevant to the serious AE must be 
recorded on the appropriate CRFs. The Investigator is obligated to pursue and 
obtain information requested by CRO  and the Sponsor in addition to that 
information reported on the eCRF . All patient s experiencing an SAE  must be 
followed up and the outcome reported. 
In the event of a n SAE , the Investigator must notify the Sponsor or designee  
immediately  (i.e. no later than 24 hours after t he siteâ€™s awareness of the 
event) ; obtain and maintain in his/her files all pertinent medical records, 
information , and medical judgments from colleagues who assisted in the 
treatment and follow -up of the patient ; provide CRO  and the study Sponsor 
with a complete case history , which includes a statement as to whether the 
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 39 of 77 If the Investigator becomes aware of any new information regarding an SAE (i.e., 
resolution, change in condition, or new treatment), a new SAE /Unanticipated Report 
Form must be completed and faxed to the Sponsor or designee within 24 hours  of 
the siteâ€™s awareness of the event . The original SAE form is not to be altered. The 
report should describe whether the event has resolved or continues and how the 
event was treated.  
10 STATISTICAL HYPOTHESES AND METHODS OF ANALYSES 
10.1 Study Populations 
10.1.1 Intent- to-Treat Population 
The Intent -to-Treat (ITT) population consists of al l patient s who a re 
randomized. All data will be included and no patient s will be excluded 
because of protocol violations. The ITT population will be analyzed as 
randomized and will be used for the efficacy analyses.   
10.1.2 Safety Population 
The Safety population includes all r andomized patient s who received at least 
one dose  of investigational treatment. The Safety population will be analyzed 
as treated and will be used for the safety analyses.  No data will be excluded 
for any reason.  
10.1.3 Per Protocol Population 
The Per Protocol (PP) population is a subset of the ITT population and includes patient s who remain in the study through Visit 5 (Day 15) with no 
major protocol violations that would affect the assessment of the primary efficacy endpoints  of the study. Patient s without majo r protocol violations 
thought to affect the primary efficacy outcome who discontinue the study due to lack of efficacy will be analyzed in the PP analysis with missing data after discontinuation imputed as failures for success/failure endpoints and will be  
imputed using last observation carried forward ( LOCF ) for other endpoints. 
Otherwise, this population will be analyzed as treated using observed data only for confirmatory analyses.  
10.2 Unit of Analysis 
The unit of analysis in this study will be the study eye for all efficacy and safety 
summaries.  Additionally, non- ocular AEs will be presented at the patient  level. Non-
study eye safety summaries will also be presented as appropriate.   
10.3 General Imputation Methods  
The primary analyses of all efficacy data will use LOCF to impute missing data; data for visits after a patient  is discontinued for lack of efficacy will be imputed as 
57$2SKWKDOPLF6XVSHQVLR Q     5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO&     $PHQGPHQW)HE 

&RQILGHQWLDO  3DJHRI IDLOXUHVIRUVXFFHVVIDLOXUHHQGSRL QWVDQGZLOOEHLPSXWHGXVLQ J/2&)IRURWKHU
HQGSRLQWV 7R FKHFN UREXVWQHVV RI UHVXOWV VHQVLWLYLW\ DQDO\VHV  RI WKH SULPDU\
HIILFDF\GDWDZLOOLQFOXGHDQDO\VHVRIREVHUYHGGDWDRQO\LPSX WLQJGDWDIURPSDWLHQW
YLVLWVDIWHUGLVFRQWLQXDWLRQIRU ODFNRIHIILFDF\DVIDLOXUHV 2WKHULPSXWDWLRQPHWKRGV
PD\EHDSSOLHGDVDGGLWLRQDOVHQVLWLYLW\DQDO\VHV
3HU3URWRFRODQDO\VHVZLOOXV HREVHUYHGGDWDRQO\ZLWKWKHH[F HSWLRQRISDWLHQWVZKR
KDYHPLVVLQJGDWDGXHWRGLVFRQ WLQXDWLRQIRUODFNRIHIILFDF\ IRUWKHVHSDWLHQWV
PLVVLQJGDWDDIWHUGL VFRQWLQXDWLRQZLOOEH LPSXWHGDVIDLOXUHV 
(IILFDF\9DULDEOHV
7KHSULPDU\HIILFDF\YDULDEOHVDUH
$EVHQFHRIDQWHULRUFKDPEHUFH OOVLHVFRUHRIÂµÂ¶DW9LVLW 'D\IRU
D7KHFRQFHQWUDWLRQRI57$ 2SKWKDOPLF6XVSHQVLRQFRPSDUH G
WRSODFHER
E7KHFRQFHQWUDWLRQRI57$ 2SKWKDOPLF6XVSHQVLRQFRPSDUH G
WRSODFHER
$EVHQFHRISDLQLHVFRUHRIÂµ Â¶DW9LVLW'D\IRU
F7KHFRQFHQWUDWLRQRI57$ 2SKWKDOPLF6XVSHQVLRQFRPSDUH GWR
SODFHERWREHWHVWHGLIDLV VWDWLVWLFDOO\VLJQLILFDQWLQID YRURIWKHDFWLYH
DUP
G7KHFRQFHQWUDWLRQRI57$ 2SKWKDOPLF6XVSHQVLRQFRPSDUH GWR
SODFHERWREHWHVWHGLIELVVWDWLVWLFDOO\VLJQLILFDQWLQID YRURIWKHDFWLYH
DUP
6HFRQGDU\HIILFDF\YDULDEOHVLQFOXGH
$EVHQFH RI DQWHULRU FKDPEHU FHOOV DW 9LVLWV   RU  'D\V   R U  
UHVSHFWLYHO\
$EVHQFHRISDLQDW9LVLWV RU'D\VRUUHVSHFWLY HO\
$EVHQFHRIIODUHDW9L VLWVRU'D\VRUUH VSHFWLYHO\
6DIHW\9DULDEOHV
7KHVDIHW\YDULDEOHVDUH
â€¢6OLW/DPS([DPLQDWLRQ
â€¢3LQKROH9LVXDO$FXLW\
â€¢,QWUDRFXODU3UHVVXUH
â€¢'LODWHGLQGLUHFWRSKWKDOP RVFRSLFH[DPLQDWLRQ
â€¢$(V
6WDWLVWLFDO+\SRWKHVHV
+ 7KHGLIIHUHQFHEHWZHHQVWXG\H\HVWUHDWHGZLWKWKHFRQF HQWUDWLRQRI
57$2SKWKDOPLF6XVSHQVLRQDQG VWXG\H\HVWUHDWHGZLWKSODFH ERLQ
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 41 of 77 the proportion of study eyes with absence of anterior chamber cells (score 
of 0) at Visit 5 (Day 15) = 0.  
HA11: The difference, between study eyes treated with the 1.0% concentration of RTA 408 Ophthalmic Suspension and study eyes treated with placebo  in 
the proportion of study eyes with absence of anterior chamber cells (score of 0) at Visit 5 (Day 15) â‰  0, with superiority claimed if the difference is 
greater than 0 (RTA 408 Ophthalmic Suspension â€“ Placebo ). 
H
012: The difference, between study eyes treated with the 0.5% concentration of RTA 408 Ophthalmic Suspension and study eyes treated with Placebo , in 
the proportion of study eyes with absence of anterior chamber cells (score of 0) at  Visit 5 (Day 15) = 0.  
H
A12: The difference, between study eyes treated with the 0.5% concentration of RTA 408 Ophthalmic Suspension and study eyes treated with placebo  in 
the proportion of study eyes with absence of anterior chamber cells (score of 0) at Visit 5 (Day 15) â‰  0, with superiority claimed if the difference is 
greater than 0 (RTA 408 Ophthalmic Suspension â€“ Placebo ). 
and 
H
021: The difference, between study eyes treated with the 1.0% concentration of RTA 408 Ophthalmic Suspension and study eyes t reated with placebo  in 
the proportion of study eyes with absence of pain (score of 0) at Visit 3 (Day 4) = 0.  
H
A21: The difference, between study eyes treated with the 1.0% concentration of RTA 408 Ophthalmic Suspension and study eyes treated with placebo  in 
the proportion of study eyes with absence of pain (score of 0) at Visit 3 (Day 4) â‰  0, with superiority claimed if the difference is greater than 0 
(RTA 408 Ophthalmic Suspension â€“ Placebo ). 
H
022: The difference, between study eyes treated with the 0.5% concentration of RTA 408 Ophthalmic Suspension and study eyes treated with placebo  in 
the proportion of study eyes with absence of pain (score of 0) at Visit 3 (Day 4) = 0.  
H
A22: The difference, between study eyes treated with the 0.5% concentration of RTA 408 Ophthalmic Suspension and study eyes treated with placebo  in 
the proportion of study eyes with absence of pain (score of 0) at Visit 3 (Day 4) â‰  0, with superiority claimed if the difference is greater than 0 
(RTA 408 Ophthalmic Suspension â€“ Placebo ). 
The primary analyses will first test the difference in the proportion of patient s with 
absence of anterior chamber cells in the study eye between the 1.0% concentration of RTA 408 Ophthalmic Suspension and placebo  and between the 0.5% concentration 
of R TA 408 Ophthalmic Suspension and placebo  at Visit 5 (Day 15) using the 
Pearson chi -squared statistic.  
If the proportion of patients with a grade of â€˜0â€™ for anterior chamber cells is 
statistically significantly higher for the 1.0% concentration versus placebo at a 1 -
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 43 of 77 10.9 Demographics and Baseline Medical History 
Patient  demographics: gender, race, ethnicity, and age will be presented using 
discrete summary statistics. Age will also be presented using continuous summary 
statistics.  
Non-ocular and ocular (study eye and fellow eye) medical history will be 
summarized by treatment group using discrete summaries.  
10.10  Primary Efficacy Analyses 
The primary efficacy variables, study eyes with absence of anterior chamber cells at Visit 5 (Day 15) and study eyes with absence of pain at Visit 3 (Day 4), will be 
summariz ed using discrete summary statistics, including 90% asymptotic normal 
confidence intervals for each treatment group. The primary efficacy analyses will first test the difference in proportion of study eyes with a grade of â€˜0â€™ in anterior chamber cells betw een the 1.0% concentration of RTA 408 Ophthalmic Suspension 
and placebo  and between the 0.5% concentration of RTA 408 Ophthalmic 
Suspension and placebo  at Visit 5 (Day 15) using the Pearson chi- squared statistic.  
If the proportion of patients with a grade of â€˜0â€™ for anterior chamber cells is 
statistically significantly higher  for the 1.0% concentration versus placebo at a 1 -
sided alpha=0.10, then the hierarchical hypothesis testing will compare the proportion of patients with absence of ocular pain at Visi t 3 (Day 4) between the 
1.0% concentration of RTA 408 Ophthalmic Suspension and placebo  using the 
Pearson chi -squared statistic at a 1 -sided alpha=0.10.   
If the proportion of patients with a grade of â€˜0â€™ for anterior chamber cells is 
statistically significantly higher for the 0.5% concentration versus placebo at a 1 -
sided alpha=0.10, then the hierarchical hypothesis will compare  the proportion of 
patient s with absence of ocular pain at Visit 3 (Day 4) between the 0.5% 
concentration of RTA 408 Ophthalmic Suspension and placebo  using the Pearson 
chi-squared statistic at a one-sided alpha=0.10.   
Additionally, 95% confidence intervals will be constructed around the difference in proportions for each primary outcome using asymptotic normal approximations. Fishe râ€™s exact tests will be employed in cases of expected counts less than five.  
If the test of the difference in the proportion of study eyes with absence of anterior chamber cells is statistically significant in favor of the 1.0% or 0.5% concentration 
of RTA  408 Ophthalmic Suspension versus placebo , then the study will be 
considered a success and the concentration (s) of RTA 408 Ophthalmic Suspension 
showing statistical significance will be declared to be superior to placebo  in the 
proportion of study eyes with absence of anterior chamber cells at Visit 5 (Day 1 5). 
Additionally, a Cochran- Armitage test will be used to test for trend separately in the 
proportion of study eyes with absence of anterior chamber cells and the proportion of study eyes with absence of pain with increasing active concentration, using all three treatment groups. 
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 44 of 77 10.11  Secondary Efficacy Analyses 
The secondary efficacy variables will be summarized at Days 4, 8, and 21 for 
absence of anterior chamber cells and  at Days 8, 15 and 21 for absence of ocular 
pain, similarly to the primary efficacy summaries. Additionally, anterior chamber 
cell grade and ocular pain score at each visit and change from baseline will be summarized using continuous and discrete summary s tatistics.  
Absence of anterior chamber flare and anterior chamber flare grade and the sum of anterior chamber cell and flare grade, including absence of both anterior chamber cell and flare will be summarized similarly to anterior chamber cells and pain at each 
visit.  
10.12  Safety Analyses 
The primary safety analysis will summarize ocular treatment- emergent AEs 
(TEAEs) in the study eye for all treated patient s using discrete summaries at the 
patient - and event -level by system organ class and preferred term for each treatment 
group. A TEAE will be defined as occurring on or after the day that treatment is initiated.  An additional analysis will investigate ocular AEs for the non -study eye. 
Non-ocular TEAEs will be summarized using discrete summaries at the patient - and 
event -level by system organ class and preferred term for each treatment group. 
Treatment -related ocular and non -ocular TEAEs will be summarized similarly. 
Ocular and non- ocular TEAEs will also be summarized by severity.  
The IOP data will be summarized  at each visit using both continuous summaries 
(including change from baseline) and discrete summaries (including the proportion of patient s with change in IOP from baseline â‰¥ 10 mm Hg and the proportion of 
patient s with an IOP â‰¥ 30 mm Hg that occurs at an y time following instillation of 
study treatment) as well as shift tables.  
Slit lamp biomicroscopy and dilated indirect ophthalmoscopic examination  measures 
will be summarized at each visit using discrete summary statistics.  
Visual acuity data will be summarized at each visit, using discrete summaries, including change from baseline in the number of lines and the proportion of patient s 
with change from previous visit of â‰¥ 2 lines. 
10.13  Subgroup Analysis 
No subgroup analyses are planned. 
10.14  Interim Analysis 
No inter im analyses are planned.  
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 45 of 77 11 COMPLIANCE WITH GOOD CLINICAL PRACTICES, 
ETHICAL CONSIDERATIONS , AND ADMINISTRATIVE 
ISSUES  
This study will be conducted in compliance with the protocol, Good Clinic al 
Practices (GCPs), including the International  Conference on  Harmonization (ICH) 
Guidelines , and in general, consistent with the  Declaration of Helsinki . In addition, 
all applicable local, state, and federal requirements relevant to the use of study drugs  
in the countries involved will be adhered to. 
11.1 Protection of Human Subjects  
11.1.1 Patient  Informed Consent 
Informed consent must take place before any study specific procedures are 
initiated. Signed and dated written informed consent must be obtained from 
each patient  and/or from the  patient â€™s parent or legal guardian pri or to 
enrollment into the study. If the patient  is under the legal age of consent, the 
consent form must be signed by a legal guardian or as required by state and/or 
local laws and regulations.  
All informed consent forms must be approved for use by the Sponsor and 
receive approval/favorable opinion from  an IRB/IEC prior to their use. If the 
consent form requires revision ( e.g., due to a protocol amendment or 
significant new safety information) , it is the Investigator â€™s responsibility to 
ensure that the amended informed consent is reviewed and approved by Sponsor prior to submission to the governing IRB/IEC and that it is read, 
signed and dated by all patient s subsequently enrolled in the study as well as 
those currently enrolled in the study. 
If informed consent is taken under special circumstances (oral informed 
consent), then the procedures to be followed must be determined by CRO  and 
study Sponsor and provided in writing by CRO  and study Sponsor prior to the 
consent process. 
11.1.2 Institutional Review Board  (IRB)  Approval 
This study is to be conducted in accordance with Institutional  Review Board 
regulations (U.S. 21  CFR Part 56.103). The Investigator must obtain  
appropriate IRB approval before  initiating the study and re -approval at least 
annually. 
Only an IRB/ERC approved version of the informed consent form will be 
used. 
11.2 Ethical Conduct of the Study 
This study will be conducted in accordance with the ethical principles that originated 
with the Declaration of Helsinki.  
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 46 of 77 11.3 Patient Confidentiality 
All personal study patient  data collected and processed for the purposes of this study 
should be maintained by the Investigator and his/her staff with adequate precautions 
as to ensure that the confidentiality of the data in accordance with local, state, and 
federal laws  and regulations. 
Monitors, auditors and other authorized representatives of CRO , the Sponsor , the 
IRB/IEC approving this study, the FDA, the DHHS, other domestic government 
agencies, and other foreign regulatory agen cies will be granted direct access to the 
study patient â€™s original medical and study records for verification of the data and/or 
clinical trial procedures. Access to this information will be permitted to the 
aforementioned individuals t o the extent permitted by law.  
A report of the results of this study may be published or sent to the appropriate health authorities in any country in which the study drug  may ultimately be 
marketed, but the patient â€™s identity will not be  disclosed in these documents. 
11.4 Documentation 
Source documents may include a patient â€™s medical records, hospital charts, clinic 
charts, the Investigator â€™s study patient  files, as well as the results of diagnostic tests 
such as X -rays, laboratory tests , and E CGs. The Investigator â€™s copy of the C RFs 
serves as the Investigator â€™s record of a patient â€™s study -related data.  
11.4.1 Retention of Documentation 
All study related correspondence, patient records, consent forms, record of the distribution and use of all study drug  and copies of CRFs  should be 
maintained on file for at least two years after the last appr oval of a marketing 
application  in an ICH region and until there are no pending or contemplated 
marketing application s in an ICH region; or until at least two years have 
elapsed since th e formal discontinuation of clinical development of the 
investigational product. These documents will be retained for a longer period if required by the applicable regulatory requirements or by an agreement with the Sponsor. It is the responsibility of the  Sponsor to inform the 
Investigator /institution as to when th ese documents no longer need to  be 
retained.  
If the responsible Investigator retires, relocates, or for other reasons withdraws from the responsibility of keeping study records, custody must be transferred to a person who w ill accept the responsibility. The Sponsor must be notified in 
writing of the name and address of the new custodian. 
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 47 of 77 11.5 Labeling, Packaging, Storage, Accountability, and Return or 
Disposal of Study Drug  
11.5.1 Labeling/ Packaging  
Each study drug kit will be labeled with a 5-digit study drug kit number and 
will contain one bottle of study drug. All bottles of active and placebo 
treatment will be identical in appearance and will be packaged in identical 
containers. The study drug kit and each bottle will have a label bearing 
information meeting applicable regulatory requirements. Study drug bottles 
will come with direction s for use and other appropriate information on each 
part. Study drug will be packaged and labeled based on the randomization list generated prior to the start of the study.   
11.5.2 Storage of Study Drug  
The study drug  product must be stored upright at 2Â° to 8Â°C  (36Â° to 46Â° F) , in a 
refrigerator, protected from freezing,  protected  from strong light, and stored in 
a secure area accessible only to the Investigator and his /her designees. The 
study drug  product will be administered only to patient s entered into the 
clinical study, in accordance with the conditions specified in this  protocol. 
11.5.3 Accountability of Study Drug  
The study drug  is to only be prescribed by the Principal Investigator  or his/her 
named sub-Investigator (s), and is to only be used in accordance with this  
protocol. The study drug  must only be distributed to patient s properly 
qualified under this protocol to receive study drug. 
The Investigator  must keep an accurate accounting of the study drug received 
from the suppl ier. This includes the amount of study drug  dispensed to 
patient s, amount of study drug  returned to the Investigator  by the patient s, and 
the amount returned or disposed upon the completion of the study. A detailed 
inventory must be completed for the study drug . 
11.5.4 Return or Disposal of Study Drug  
All study drug will be returned to the Sponsor or their designee o r destroyed at 
the study site. The return or disposal of study drug will be specified in writing.  
11.6 Recording of Data on Source Documents and eCRFs  
The Investigator  is responsible for ensuring that study data is completely and 
accurately  recorded on each patient â€™s eCRF , source document, and all study -related 
material. All study data  should also be attributable, legible , contemporaneous, and 
original. Recorded datum should only be corrected in a manner that does not 
obliterate, destroy, or render illegible the previous entry ( e.g., by drawing a single 
line through the incorrect entry and writing the revision next to the corrected data). 
An individual  who has corrected a data entry  should make clear who made the 
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 48 of 77 correction and when, by adding  to the correction his/her initials as well as the date of 
the correction.  
11.7 Handling of Biological Specimens 
Not applicable.  
11.8 Publications 
Authorship and manuscript  composition will reflect cooperation among all parties 
involved in the study. Authorship will be established before writing the manuscript. 
The Sponsor will have the final decision regarding the manuscript and publication. 
  
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 49 of 77 12 REFERENCES  
1. Liu J. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 
1995;49:57-68. 
2. Honda T, Rounds BV, Gribble GW, Suh N, Wang Y, Sporn MB. Design and synthesis of 2- cyano -3,12-dioxoolean-1,9- dien-28-oic acid, a novel and highly 
active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1998;8:2711-2714. 
3. Jabs, D.A., R.B. Nussenblatt, J. T. Rosenbaum. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical da ta. Results of the First International Workshop. Am J 
Ophthalmol 2005, 140(3):509-516. 
4. National Institutes of Health (NIH). Numeric Pain Rating Scale
 (NPRS). Warren 
Grant Magnuson Clinical Center. Pain Intensity Instruments. July 2003.  
  
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 50 of 77 0 2 3 4 5 6 1 7 8 9 10
None Mild Moderate SevereAPPENDIX 1: EXAMI NATION PROCEDURES  
OCULAR PAIN GRADING SCALE (STUDY EYE)  
Ocular Pain will be assessed by the patient  at screening and at each follow -up visit, 
utilizing a Numerical Pain Rating Scale1 graded from 0 to 10. Patient s will assess the 
level of pain they are experiencing in the study eye at the time of the assessment.  Patients 
may only select whole numbers on the scale.  
The examiner will ask the patient  the following question related to Figure 1 :On a 
scale of 0 to 10, in which 0 is no pain and 10 is the worst possible or unbearable 
pain, please mark on the scale the whole number that best describes the pain or 
discomfort you are feeling in the operated eye at this time. The middle of the scale (around 5) can be used to describe â€œmoderate painâ€.  
Figure 1  Ocular Pain Grading Scale  
 
 
 
 
 
  
 
 
 
At the screening assessment visit, the patient  will be asked about the eye scheduled for 
surgery. 
The examiner will record the number selected by the patient  on the appropriate eCRF. 
  
1 Reference 4. National Institutes of Health (NIH). Numeric Pain Rating Scale (NPRS). . Warren Grant Magnuson 
Clinical Center. Pain Intensity Instruments. July 2003.  
  
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 51 of 77 APPENDIX 1 (CONTINUE D) 
PIN-HOLE VISUAL ACUITY PROCEDURES (EACH EYE)  
Pin-hole, LogMAR visual acuity must be assessed using an ETDRS chart. The procedure 
used will be consistent with the recommendations provided for using the ETDRS eye 
chart. Pin -hole visual acuity should be evaluated at the beginning of each visit in the 
study (i.e., prior to slit lamp examination). Pin -hole visual acuity testing should be done 
with a pin -hole occluder. 
Equipment 
The visual acuity chart to be used is the ETDRS chart. If smaller reproduction (18" by 
18", e.g., from Prevent Blindness) wall charts are used, the patient  viewing distance 
should be exactly 10 feet (or as specified by the manufacturer). In ALL cases, for purposes of standardizing the testing conditions during the study, all sites must use only 
the 'R' charts, and the right eye should be tested first. For reflectance (wall) charts, the chart should be placed frontally and well- illuminated.  
Measurement Techniqu e 
The chart should be at a comfortable viewing angle. A pin- hole occluder should be 
applied to the right eye which should be tested first. The patient  should attempt to read 
each letter, line- by-line, left to right, beginning with line 1 at the top of the chart. The 
patient  should be told that the chart has letters only, no numbers. If the patient  reads a 
number, he or she should be reminded that the chart contains no numbers, and the examiner should then request a letter in lieu of the number.  
The patient  should be asked to read slowly, so as to achieve the best identification of each 
letter. He/she is not to proceed to the next letter until he/she has given a definite response. If the patient  changes a response (e.g., â€œthat was a â€˜Câ€™ not an â€˜Oâ€™â€) before he has read 
aloud the next letter, then the change must be accepted. If the patient  changes a response 
having read the next letter, then the change is not accepted. The examiner should never 
point to the chart or to specific letters on the chart during the test.  
A maximum effort should be made to identify each letter on the chart. When the patient  
says he or she cannot read a letter, he or she should be encouraged to guess. If the patient  
identifies a letter as one of two letters, he or she should be asked t o choose one letter and, 
if necessary, to guess. When it becomes evident that no further meaningful readings can be made, despite encouragement to read or guess, the examiner should stop the test for that eye. However, all letters on the last line should be attempted as letter difficulties vary and the last may be the only one read correctly. The number of letters missed or read incorrectly should be noted. 
  
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 52 of 77 APPENDIX 1 (CONTINUE D) 
PIN-HOLE VISUAL ACUITY PROCEDURES (cont.)  
LogMAR Visual Acuity Calculations  
The last line in which a letter is read correctly will be taken as the base logMAR reading. 
To this value will be added the number "N x 0.02" where 'N' represents the total number of letters missed up to and included in the last line read. This total sum r epresents the 
logMAR visual acuity for that eye.  
For example: Patient correctly reads 4 of 5 letters on the 0.2 line, and 2 of 5 letters on the 
0.1 line. 
Base LogMAR  = 0.1  
N (total number of letters incorrect on line 0.2 as well as 0.1)  
  
= 4 
N x T (T=0.02)  = 0.08  
Base logMAR + (N x T)  = 0.1 + 0.08  
logMAR VA  = 0.18  
Repeat the procedure for the left eye.  
In order to provide standardized and well -controlled assessments of visual acuity during 
the study, all visual acuity assessments at a single site must be consistently done using the same lighting conditions and pin- hole during the entire study. If the sam e conditions and 
use of pin- hole cannot be used, the reason for the change in condition and pin hole should 
be documented. 
  
57$2SKWKDOPLF6XVSHQVLR Q     5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO&     $PHQGPHQW)HE 

&RQILGHQWLDO  3DJHRI $33(1',;&217,18('
6/,7/$03%,20,&526&23<($&+(<(
6OLWODPSELRPLFURVFRS\ZLOOEH SHUIRUPHGGXULQJWKHVWXG\2E VHUYDWLRQVZLOOEHJUDGHG
DV1RUPDORU$EQRUPDO$OODEQRUPD OILQGLQJVRWKHUWKDQWKHHQ GSRLQWVEHLQJDVVHVVHG
E\WKHVWXG\VFDOHVDQWHULRUFKDPEHUFHOOVDQGIODUHZLOOEH GRFXPHQWHGRQHDFK
SDWLHQWÂ¶VVRXUFHGRFXPHQWDQGFR UUHVSRQGLQJHOHFWURQLFFDVHUHS RUWIRUPH&5)$OO
DEQRUPDOILQGLQJVZLOOEHFDWHJRU L]HGDVFOLQLFDOO\VLJQLILFDQW ILQGLQJVWKDWPD\LQWHUIHUH
ZLWKVWXG\SDUDPHWHUVRURWKHU ZLVHFRQIRXQGWKHGDWDDVGHWHUPL QHGE\WKHLQYHVWLJDWRU
DQGQRWFOLQLFDOO\VLJQLILFDQW
7KHIROORZLQJZLOOEHH[DPLQHGDWHDFKYLVLW
â€¢(\HOLG
â€¢&RQMXQFWLYD
â€¢&RUQHD
â€¢,ULV
â€¢/HQV
â€¢$QWHULRUFKDPEHU
([WHUQDO H[DPLQDWLRQ DQG ELRPLFURVFRS\ ZLOO EH SHUIRUPHG XVLQJ D VOLW ODPS
0DJQLILFDWLRQZLOOEHFRQVLVWHQWZLWKVWDQGDUGFOLQLFDOSUDFWLF H7KHSDWLHQWZLOOEH
VHDWHG

RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 54 of 77 APPENDIX 1 (CONTINUE D) 
DURING SLIT -LAMP BIOMICROSCOPY: ANTERIOR CHAMBER CELLS 
AND FLARE (STUDY EYE)  
The slit beam observations should be assessed in a dark room using a slit beam of 1.0 mm 
height and 1.0 mm width with maximum luminance, with 16x magnifica tion, 1x1mm 
oblique high intensity beam fluorescein dye is to be instilled into the ocular cul -de-sac, or 
alternatively, fluorescein strips may be used to facilitate this examination.   
Anterior Chamber Cells and Flare  
The anterior chamber cell count will be recorded as the actual number of cells observed if 
fewer than 10 cells are seen (only white blood cells should be counted; red blood cells and pigment cells should not be counted). Flare will be graded using the SUN* Working Group grading scheme. 
 
Anter ior Chamber Cells  
Grade  Number of Cells in Field  
0 0 cell s 
1 1 to 10 cells  
2 11 to 20 cells  
3 21 to 50 cells  
4 > 50 cells  
 
*Reference 3.  Standardization of the Uveitis Nomenclature (SUN) : Jabs et al. 2005.  
 INTRAOCULAR PRESSURE (IOP) PROCEDURES  (EACH EYE)  
Applanation tonometry, Goldmann tonometer required. Do NOT use non- contact 
tonometry. 
  Flare  
Grade  Description  
0 None  
1+ Faint  
2+ Moderate  
iris and lens details clear  
3+ Marked  
iris and lens details hazy  
4+ Intense  
fibrin or plastic aqueous  
57$2SKWKDOPLF6XVSHQVLR Q     5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO&     $PHQGPHQW)HE 

&RQILGHQWLDO  3DJHRI $33(1',;&217,18('
',/$7(',1',5(&723+7+$/026&23 ,&(;$0,1$7,21($&+(<(

'LODWHGLQGLUHFWRSKWKDOPRVFRSLF H[DPLQDWLRQZLOOEHSHUIRUPHG DVLQGLFDWHGLQWKHVWXG\
IORZFKDUW LQ $SSHQGL[  DIWHU WKH SDWLHQW ,&)DXWKRUL]DWLRQ PH GLFDO
KLVWRU\GHPRJUDSKLFVXULQHSUHJ QDQF\WHVWLIDSSOLFDEOHSLQ KROHYLVXDODFXLW\VOLW
ODPSELRPLFURVFRS\DQGWRQRPHWU\7KHH[DPLQDWLRQZLOOQRWEH SHUIRUPHGXQWLOWKH
SDWLHQWÂ¶VH\HVDUHGHHPHGVXIILFLHQWO\GLODWHGLQWKHRSLQLRQR IWKHLQYHVWLJDWRU7KH
LQYHVWLJDWRUZLOOQRWHDQ\ILQGLQJVSUHVHQWDQGZKHWKHURUQRW WKHILQGLQJVDUHFOLQLFDOO\
VLJQLILFDQWRUQRWFOLQLFDOO\VLJQLILFDQW)LQGLQJVZKLFKDUH FOLQLFDOO\VLJQLILFDQWZLOOEH
GHVFULEHG7KHIROORZLQJZLOOEHH[DPLQHG
â€¢9LWUHRXV
â€¢5HWLQD
â€¢0DFXOD
â€¢&KRURLG
â€¢2SWLF1HUYH


RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 56 of 77 APPENDIX 2:  SCHEDULE OF VISITS AND MEASUREMENTS  
Study Parameter  Visit 1  
(â‰¥ -28 Days 
Prior to 
Surgery)  Visit 2  
(Day 1,  
24 Â± 6 hrs  
Post-
Surgery)  Visit 3 
(Day 42) Visit 4 
(Day 82) Visit 5 
(Day 153) Visit 6  
(Day 212, 
Exit or Early 
Exit Visit) 
Informed Consent/  
HIPAA  X      
Demographic Data  X      
Medical and Medication 
History  X      
Urine Pregnancy Test (for 
females of childbearing 
potential)  X     X 
Review of Inclusion and 
Exclusion Criteria  X X     
Medical and Medication 
History Update   X X X X X 
Ocular Pain Assessment  X X X X X X 
Pin-hole Visual Acuity  X X X X X X 
Slit Lamp Biomicroscopy  X X X X X X 
Ocular Inflammation 
Assessment  of Anterior 
Chamber Cell and Flare (at 
Slit-lamp Biomicroscopy)  X X X X X X 
Intraocular Pressure 
Assessment  X X X X X X 
Randomization of Study 
Patient s  X     
Dilated Indirect 
Ophthalmoscopic 
Examination  X     X 
Study Drug Instillation1  X     
Study Drug and 
Compliance Diary 
Instructions and 
Dispensation   X     
AE Query   X X X X X 
Review of Study Drug 
Compliance Diary    X X X X 
Collection of Study Drug 
and Compliance  Diary      X X4 
Exit from Study       X 
1First study drug dose will be instilled in -office at Visit 2. Patient s will instill study drug twice  daily at -
home in the morning and evening (approximately 12  hrs apart) between study visits , from Day 1  through 
Day 1 4. 
2Â± 1 Day  
3 + 1 Day 
4 In case of early termination or if patient did not return  study drug prior to Visit 5.   
57$2SKWKDOPLF6XVSHQVLRQ
 5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO& $PHQGPHQW)HE

&RQILGHQWLDO  3DJHRI $33(1',;35272&2/$0(1'0(176
5$7,21$/()25$0(1'0(17
7KHSXUSRVHRIWKHSURW RFRODPHQGPHQWLVWRPDNHDGPLQLVWUDWLYH XSGDWHVWKURXJKRXW([FOX VLRQFULWHULDDQGKDG
DGGLWLRQDOH[FOXVLRQDU\LWHPVV SHFLILHGDGGLWLRQDOVWXG\GUXJ GRVLQJLQVWUXFWLRQVZHUHDG GHGWR6HFWLRQDGGLWLRQDOGHW DLOV
UHJDUGLQJHVFDSHPHGLFDWLRQV ZHUHVSHFLILHGLQ6HFWLRQD QG6HFWLRQZDVGHOHWH GJLYHQ6SRQVRU
3KDUPDFRYLJLODQFH ZLOO
DVVHVVIRUDGYHUVHHYHQWH[SHFWHGQHVV
6800$5<2)&+$1*(6
,QWKHWDEOHEHORZWKHSURWRFRO WH[WZDVDPHQGHGE\WKHIROORZL QJFRQYHQWLRQV
â€¢'HOHWLRQVWRRULJLQDOWH[WDUHL QGLFDWHGE\VWULNHWKURXJKOHWW HUV
â€¢$GGLWLRQVWRDPHQGHGWH[WDUHLQGLFDWHGE\ EROGOHWWHUV
â€¢5HSODFHPHQWRIZRUGLQJLQWKHDPHQGHGWH[WDUHLQGLFDWHGE\ EROGDQGLWDOLFL]HG OHWWHUV
RTA 408 Ophthalmic Suspension  Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307  Amendment 1 : 10-Feb-2014 
 
Confidential   Page 58 of 77  
Section  Reason for 
Amendment  Protocol Currently Reads Amended Text  
Title Page  Administrative 
update  [blank]  Amendment 1:   10-Feb-2014  
Header  Administrative 
update  RTA 408 Sterile Ophthalmic Suspension  RTA 408 Sterile  Ophthalmic Suspension  
Header  Administrative 
update  Original Protocol: 21 -Nov-2013  Amendment 1 : 10-Feb-2014  
Synopsis  
pg 5 â€“ Inclusion 
Criteria #4  Administrative 
update Have undergone unilateral cataract extraction via phacoemulsification on the day prior to study enrollment/randomization; 
 Have undergone unilateral cataract extraction via 
phacoemul sification and posterior chamber 
intraocular lens (PCIOL) implantation in the 
study eye on the day prior to study 
enrollment/randomization; 
Synopsis  
pg 5 â€“ Inclusion 
Criteria #5  Administrative 
update Have a grade of â‰¥2 in anterior chamber cell score 
on day after surgery (Day 1);  Have a grade of â‰¥2 in anterior chamber cell score on day after surgery (Day 1) in the study eye ; 
Synopsis  
pg 5 â€“ Inclusion Criteria #6  Administrative 
update Have a potential post -operative pin -hole visual 
acuity (VA) of greater than 1.0 logarithm of the minimum angle of resolution (logMAR) in the operative eye and fellow eye as measured using an 
Early Treatment for Diabetic Retinopathy Study 
(ETDRS) chart;  Have a potential post -operative pin -hole visual 
acuity (VA) of greater th an< 1.0 logarithm of the 
minimum angle of resolution (logMAR) in the 
operative eye and fellow eye as measured using 
an Early Treatment for Diabetic Retinopathy 
Study (ETDRS) chart;  
Synopsis  
pg 5 â€“ Inclusion Criteria #7  Administrative 
update (For females of childbearing potential) agree to 
have urine pregnancy testing performed at screening (must be negative) and at exit visit
1; must 
not be lactating; and must agree to use a medically acceptable form of birth control
2 throughout the 
study duration. 
________________________ (For females of childbearing potential) agree to 
have urine pregnancy testing performed at 
screening (must be negative) and at exit visit1; 
must not be lactating; and must agree to use a medi cally acceptable form of birth control
1 
throughout the study duration. 
________________________ 
RTA 408 Ophthalmic Suspension  Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307  Amendment 1 : 10-Feb-2014 
 
Confidential   Page 59 of 77 1 The subject must choose an acceptable method of 
birth control as specified in inclusion criterion 7 in 
order to continue in the study. 
2 Acceptable forms of birth control are spermicide 
with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal 
contraceptive, intrauterine device, or surgical 
sterilization of partner. For non- sexually active 
females, abstinence will be considered an 
acceptable form of birth control.  1 The subject must choose an acceptable method 
of birth control as specified in inclusion criterion 
7 in order to continue in the study. 
1 Acceptable forms of birth control are spermicide 
with barrier, oral contraceptive, injectable or 
implantable method of contraception, transdermal 
contraceptive, intrauterine device, or surgical 
sterilization of partner. For non- sexually active 
females, abstinence will be considered an 
acceptable form of birth control.  
Synopsis  
pg 6 â€“ Exclusion 
Criteria #7  Additional 
exclusion criteria added Use the following anti-inflammatory or 
immunomodulating agents systemically, or in the study eye, for the duration of the study. Washout 
periods for medications prior to surgery are as 
follows:  
a. Systemic corticosteroids: 14 days 
b. Periocular injection of any corticosteroid solution: 28 days  
c. Corticosteroid depot in the study eye: 56 days after implantation  
d. Cyclosporine: 56 days  
e. Topical ocular corticosteroid: 7 days  
f. Topical ocular NSAID: 7 days 
 Use anti -inflammatory agents, analgesics/pain 
relievers (including opioids, narcotics and 
other pain medications) or immunomodulating 
agents systemically, or in the study eye, and/or 
use medications for benign prostatic 
hyperplasia (BPH),  from the washout period 
through for the duration of the study. Washout 
periods for medications prior to surgery are as 
follows:  
a. Medications for BPH ( tamsulosin , 
silodosin, alfuzosin, finasteride) : 28 days  
b. Systemic corticosteroids: 14 days 
c. Systemic analgesics/pain relievers (e.g. , 
gabapentin, pregabalin, NSAIDs and 
opioids): 14 days 
Note: Use of acetaminophen (up to 4,000 
mg/day) and â€˜babyâ€™ aspirin (up to 81 mg/day) during the study are allowed. Use 
of an opioid during cataract surgery is allowed.  
d. Periocular injection of any corticosteroid 
solution: 28 days  
RTA 408 Ophthalmic Suspension  Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307  Amendment 1 : 10-Feb-2014 
 
Confidential   Page 60 of 77 e. Corticosteroid depot in the study eye: 56 
days after implantation  
f. Cyclosporine: 56 days 
g. Topical ocular corticosteroid: 7 days  
h. Topical ocular NSAID: 7 days  
Synopsis  
pg 7 â€“ Exclusion 
Criteria #9  Administrative 
update Have an IOP  â‰¤ 5 mmHg in either eye; Have an intraocular pressure ( IOP)  â‰¤ 5 mmHg 
in either eye;  
Synopsis  
pg 7 â€“ Exclusion 
Criteria #16  Administrative 
update Have had corneal or retinal surgery (laser or 
incisional) within the past 6 months, or be planning 
to have laser or incisional surgery during the study 
period in the study eye;  Have had corneal or retinal surgery (laser or incisional) within the past 6 months, or be 
planning to have laser or incisional surgery 
during the study period in the study eye (other than cataract surgery) ; 
Synopsis  
pg 7 â€“ Exclusion 
Criteria #17  Administrative 
update Have a scheduled surgery in the contralateral eye during the study;  Have a surgery  planned or  scheduled surgery in  
for the contralateral eye during the study; 
Synopsis  
Pg 8 â€“  
Exclusion Criteria 
#23 Additional 
exclusion criteria 
added Have undergone a vitrectomy procedure in addition 
to the cataract extraction proce dure in the study 
eye; Have undergone any other ophthalmic surgical 
procedure (e.g., vitrectomy, relaxing incisions, 
iridectomy, conjunctival excisions, use of iris 
hooks or other iris dilators, etc.) a vitrectomy 
procedure in addition to the cataract extr action 
procedure and PCIOL implantation in the study 
eye; 
Synopsis  
Pg 8 â€“  
Exclusion Criteria #24 Administrative 
update Have previously enrolled in this clinical study, or 
will be participating during the follow -up 
period in another clinical trial that could confound the treatment or outcomes of this investigation;  Have previously enrolled in this clinical study, or 
will be are planning to  participat e in another  
clinical trial during the follow-up period, in 
another clinical trial  that could confound the 
treatment or outcomes of this investigation;  
Synopsis Pg 10 â€“  
General Statistical Administrative 
update If in addition to a statistically significant test of the 
difference in the proportion of study eyes with If in addition to a statistically significant test of 
the difference in the proportion of study eyes with 
RTA 408 Ophthalmic Suspension  Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307  Amendment 1 : 10-Feb-2014 
 
Confidential   Page 61 of 77 Methods and 
Types of 
Analyses:  
Efficacy Analysis 
(5th Paragraph) 
 
 absence of anterior chamber cells at Visit 5 (Day 
15) in favor of RTA 408 Ophthalmic Suspension, 
the test of the difference in the proportion of study eyes with absence of ocular pain at Visit 3 (Day 4) 
is statistically significant in favor of RTA 408 
Ophthalmic Suspension, then RTA 408 Ophthalmic 
Suspension will be declared to be superior to 
placebo in both the proportion of study eyes with absence of anterior chamber cells at Visit 5 (Day 
15) and the proportion of study eyes with absence 
of ocular pain at Visit 3 (Day 4). absence of anterior chambe r cells at Visit 5 (Day 
15) in favor of RTA 408 Ophthalmic Suspension, 
the test of the difference in the proportion of 
study eyes with absence of ocular pain at Visit 3 
(Day 4) is statistically significant in favor of RTA 
408 Ophthalmic Suspension, then RTA 408 
Ophthalmic Suspension will be declared to be 
superior to placebo in both the proportion of 
study eyes with absence of anterior chamber cells 
at Visit 5 (Day 15) and the proportion of study 
eyes with absence of ocular pain at Visit 3 (Day 
4). 
Synopsis Pg 11 â€“ 
General Statistical 
Methods and Types of 
Analyses:  
General Considerations 
(5
th and 6th 
Paragraphs)  
 Administrative 
update The secondary efficacy variables, study eyes with 
absence of anterior chamber cells (Visits 3, 4 or 6), 
study eyes with absence of pain (Visits 4, 5 or 6) and study eyes with absence of flare (Visits 3, 4, 5 
or 6) will be summarized and analyzed similarly to 
the primary efficacy summaries and analyses. 
Additionally, anterior chamber cells and flare as 
well as pain at each visit and change from baseline will be summarized using continuous and discrete 
summary statistics.  
The sum of anterior chamber cells and flare grade 
will be summarized and analyzed similarly to 
anterior chamber cells and flare separately.  The secondary effica cy variables, study eyes with 
absence of anterior chamber cells (Visits 3, 4 or 
6), study eyes with absence of pain (Visits 4, 5 or 6) and study eyes with absence of flare (Visits 3, 
4, 5 or 6) will be summarized and analyzed 
similarly to the primary efficacy summaries and 
analyses . Additionally, anterior chamber cells and 
flare as well as pain at each visit and change from 
baseline will be summarized using continuous 
and discrete summary statistics.  
The sum of anterior chamber cells and flare grade will be summarized and analyzed  similarly to 
anterior chamber cells and flare separately.  
List of 
Abbreviations  Administrative 
update â€¦ 
BID Bis in die (twice daily)  
CFR Code of Federal Regulations â€¦ â€¦ BID Bis in die (twice daily)  
BPH Benign prostatic hyperplasia  
CFR Code of Federal Regulations 
RTA 408 Ophthalmic Suspension  Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307  Amendment 1 : 10-Feb-2014 
 
Confidential   Page 62 of 77 NSAID  Non-steroidal anti -inflammatory agent  
PDR Proliferative diabetic retinopathy  
â€¦ â€¦ 
NSAID Non -steroidal anti -inflammatory agent 
PCIOL Posterior chamber intraocular lens  
PDR Proliferative diabetic retinopathy  
... 
Section 4 
Paragraph 2  Administrative 
update . . .The Investigator will then perform a slit lamp 
biomicroscopic examination with IOP 
measurement, and grading of anterior chamber 
inflammation. A di lated indirect ophthalmoscopic 
examination will also be performed. Female 
patients of childbearing potential will be given a 
urine pregnancy test.  ...The Investigator will then perform a slit lamp biomicroscopic examination with intraocular 
pressure ( IOP) measurement, and grading of 
anterior chamber inflammation. A dilated indirect 
ophthalmoscopic examination will also be performed. Female patients of childbearing 
potential will be given a urine pregnancy test.  
Section 4 
Paragraph 3  Administrative 
update â€¦Qualifying patients (with â‰¥2 score in anterior chamber cell, IOP â‰¤22 mm Hg) will then be 
randomized to one of the following treatment 
groups (in a 1:1:1 ratio): RTA 408 Ophthalmic 
Suspension 0.5% (N=35), RTA 408 Ophthalmic Suspension 1.0% (N=35), or placebo for RTA 408 
Ophthalmic Suspension (N=35). â€¦Qualifying patients (with â‰¥2 score in anterior 
chamber cell, IOP â‰¤22 mm Hg) will then be 
randomized to one of the following treatment groups (in a 1:1:1 ratio): RTA 408 Ophthalmic 
Suspension 0.5% (N=35), RTA 408 Ophthalmic 
Suspension 1.0% (N=35), or placebo for RTA 
408 Ophthalmic Suspension (N=35). 
Section 5.3 
Inclusion Criteria 
#4 Administrative 
update Have undergone unilateral cataract extraction via 
phacoemulsification on the day prior to study 
enrollment/randomization; 
 Have undergone unilateral cataract extraction via 
phacoemulsification and posterior chamber 
intraocular lens (PCIOL) implantation in the 
study eye on the day prior to study 
enrollment/randomization; 
Section 5.3 
Inclusion Criteri a 
#5 Administrative 
update Have a grade of â‰¥2 in anterior chamber cell score 
on day after surgery (Day 1);  Have a grade of â‰¥2 in anterior chamber cell score on day after surgery (Day 1) in the study eye ; 
Section 5.3 Administrative Have a potential post -operative pin -hole visual Have a potential post -operative pin -hole visual 
RTA 408 Ophthalmic Suspension  Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307  Amendment 1 : 10-Feb-2014 
 
Confidential   Page 63 of 77 Inclusion Criteria 
#6 update acuity (VA) of greater than 1.0 logarithm of the 
minimum angle of resolution (logMAR) in the 
operative eye and fellow eye as measured using an Early Treatment for Diabetic Retinopathy Study 
(ETDRS) chart ; acuity (VA) of greater than < 1.0 logarithm of the 
minimum angle of resolution (logMAR) in the operative eye and fellow eye as measured using an Early Treatment for Diabetic Retinopathy 
Study (ETDRS) chart;  
Section 5.3 
Inclusion Criteria #7 Administrative 
update (For females of childbearing potential) agree to 
have urine pregnancy testing performed at 
screening (must be negative) and at exit visit1; must 
not be lactating; and must agree to use a medically acceptable form of birth control
2 throughout the 
study duration. 
________________________ 
1 The subject must choose an acceptable method of 
birth control as specified in inclusion criterion 7 in 
order to continue in the study. 
2 Acceptable forms of birth control are spermicide 
with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal 
contraceptive, intrauterine device, or surgical 
sterilization of partner. For non- sexually active 
females, abstinence will be considered an 
acceptable form of birth control.  (For females of childbearing potential) agree to have urine pregnancy testing performed at 
screening (must be negative) and at exit visit
1; 
must not be lactating; and must agree to use a medi cally acceptable form of birth control
1 
throughout the study duration. 
________________________ 
1 The subject must choose an acceptable method 
of birth control as specified in inclusion criterion 
7 in order to continue in the study. 
1 Acceptable forms of b irth control are spermicide 
with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal 
contraceptive, intrauterine device, or surgical 
sterilization of partner. For non- sexually active 
females, abstinence will be considered an 
acceptable form of birth control.  
Section 5.4 
Exclusion Criteria 
#7 Additional 
exclusion criteria added Use the following anti-inflammatory or 
immunomodulating agents systemically, or in the study eye, for the duration of the study. Washout 
perio ds for medications prior to surgery are as 
follows:  
a. Systemic corticosteroids: 14 days 
b. Periocular injection of any corticosteroid 
solution: 28 days  Use anti -inflammatory agents, analgesics/pain 
relievers (including opioids, narcotics and 
other pain medications) or immunomodulating 
agents systemically, or in the study eye, and/or 
use medications for benign prostatic 
hyperplasia (BPH),  from the washout period 
through for the duration of the study. Washout 
periods for medications prior to surgery are as 
RTA 408 Ophthalmic Suspension  Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307  Amendment 1 : 10-Feb-2014 
 
Confidential   Page 64 of 77 c. Corticosteroid depot in the study eye: 56 
days after implantation  
d. Cyclosporine: 56 days 
e. Topical ocular corticosteroid: 7 days  
f. Topical ocular NSAID: 7 days 
 follows:  
a. Medications for BPH ( tamsulosin , 
silodosin, alfuzosin, finasteride ): 28 days  
b. Systemic corticosteroids: 14 days 
c. Systemic analgesics/pain relievers (e.g., 
gabapentin, pregabalin, NSAIDs and 
opioids): 14 days 
Note: Use of acetaminophen (up to 4,000 mg/day) and â€˜babyâ€™ aspirin (up to 81 
mg/day) during the study are allowed. Use 
of an opioid during cataract surgery is allowed.  
d. Periocular injection of any corticosteroid 
solution: 28 days  
e. Corticosteroid depot in the study eye: 56 
days after implantation  
f. Cyclosporine: 56 days 
g. Topical ocular corticosteroid: 7 days  
h. Topical ocular  NSAID: 7 days  
Section 5.4 
Exclusion Criteria #9 Administrative 
update Have an IOP  â‰¤ 5 mmHg in either eye; 
 Have an intraocular pressure ( IOP)  â‰¤ 5 mmHg 
in either eye;  
Section 5.4 
Exclusion Criteria 
#16 Administrative 
update Have had corneal or retinal surgery (laser or 
incisional) within the past 6 months, or be planning 
to have laser or incisional surgery during the study 
period in the study eye;  
 Have had corneal or retinal surgery (laser or 
incisional) within the past 6 months, or be 
planning to have laser or incisional surgery 
during the study period in the study eye (other 
than cataract surgery) ;  
 
Section 5.4 
Exclusion Criteria 
#17 Administrative 
update Have a scheduled surgery in the contralateral eye 
during the study ;  Have a surgery  planned or  scheduled surgery in  
for the contralateral eye during the study; 
RTA 408 Ophthalmic Suspension  Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307  Amendment 1 : 10-Feb-2014 
 
Confidential   Page 65 of 77 Section 5.4 
Exclusion Criteria 
#23 Additional 
exclusion criteria added Have undergone a vitrectomy procedure in addition 
to the cataract extraction procedure in the study 
eye; Have undergone any other ophthalmic surgical 
procedure (e.g., vitrectomy, relaxing incisions, 
iridectomy, conjunctival excisions, use of iris 
hooks or other iris dilators, etc.) a vitrectomy 
procedure in addition to the cataract extraction 
procedure and PCIOL implantation in the study 
eye; 
Section 5.4 
Exclusion Criteria 
#24 Administrative 
update Have previously enrolled in this clinical study, or 
will be participating during the follow -up 
period in another clinical trial that could confound the treatment or outcomes of this investigation;  Have previously enrolled in this clinical study, or 
will be are planning to  participate  in another  
clinical trial participating  during the follow-up 
period, in another clinical trial that could 
confound the treatment or outcomes of this 
investigation;  
Section 6.1.2  
 Administrative 
update This clinical study is designed to evaluate the efficacy and safety of two concentrations of RTA 
408 Ophthalmic Suspension compared to placebo 
in the treatment of inflammation and pain following ocular surgery. To demonstrate clinical 
efficacy, RTA 408 Ophthalmic Suspension must be 
effective in eliminating anterior chamber cells (i.e. 
score of â€˜0â€™) at Visit 5 (Day 15) post-ocular 
surgery. If, in addition to absence of anterior chamber cells, RTA 408 Ophthalmic Suspension is 
also effective in elimination of ocular pain (i.e. 
score of â€˜0â€™) at Visit 3 (Day 4) post- ocular surgery, 
then absence of pain will also be claimed. This clinical study is designed to evaluate the 
efficacy and safety of two concentrations of RTA 
408 Ophthalmic Suspension compared to placebo 
in the treatment of inflammation and pain 
following ocular surgery. To demonstrate clinical 
efficacy, RTA 408 Ophthalmic Suspension must 
be effec tive in eliminating anterior chamber cells 
(i.e. score of â€˜0â€™) at Visit 5 (Day 15) post ocular 
surgery. If, in addition to absence of anterior 
chamber cells, RTA 408 Ophthalmic Suspension 
is also effective in elimination of ocular pain (i.e. 
score of â€˜0â€™) at Visit 3 (Day 4) post ocular 
surgery, then absence of pain will also be 
claimed.  
Section 7.1.2 3rd 
Bullet Point  Additional dosing 
instructions specified  Instructions to patients on study drug administration will include: Remove from refrigerator.  SHAKE  WELL BEFORE 
USE.   Instill one drop twice daily for 14 days in the Instructions to patients on study drug administration will include: Remove from refrigerator.  SHAKE WELL BEFORE 
USE.   Instill one drop twice daily for 14 days in 
57$2SKWKDOPLF6XVSHQVLRQ 5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO& $PHQGPHQW)HE

&RQILGHQWLDO  3DJHRI PRUQLQJDQGHYHQLQJDSSUR[LPDWHO\KRXUV
DSDUWLQWKHH\HWKDWXQGHUZHQWVXUJHU\5HWXUQ
GUXJWRUHIULJHUDWRUIRUVWRUDJHDIWHUHDFKXVH'LVFRQWLQXHXVHRIWKHVWXG\GUXJDIWHU
FRPSOHWLQJVHFRQGGRVHRQ'D\.HHSRXWRI
UHDFKRIFKLOGUHQWKHPRUQLQJDQGHYHQLQJDSSUR[LPDWHO\KRXUV
DSDUWLQWKHH\HWKDWXQGHUZHQWVXUJHU\ 6WXG\
GUXJPXVWEHQRWEHLQVWLOOHGZLWKLQPLQXWHV
RIDIWHULQVWLOODWLRQRIDQ\RWKHURFXODU
PHGLFDWLRQVRUDUWLILFLDOWHDUV 5HWXUQWKHVWXG\
GUXJWRUHIULJHUDWRUIRUVWRUDJHDIWHUHDFK
XVH'LVFRQWLQXHXVHRIWKHVWXG\GUXJDIWHU
LQVWLOOLQJFRPSOHWLQJ WKHVHFRQGGRVHRQ'D\
.HHSRXWRIUHDFKRIFKLOGUHQ
6HFWLRQ
$GPLQLVWUDWLYH
XSGDWH6WXG\VWDIIZLOOFRQILUPWKDWWKHSDWLHQWKDVQRW
XVHGSULRUWR'D\IRUWKHLQGLFDWHGZDVKRXW
LQWHUYDODQGIRUWKHGXUDWLRQRIWKHVWXG\DQ\RIWKH
IROORZLQJGLVDOORZHGPHGLFDWLRQVV\VWHPLFDOO\RU
LQWKHVWXG\H\HJU RXSHGE\ZDVKRXWSHULRG
Â«
GD\V
â€¢6\VWHPLFFRUWLFRVWHURLGV

GD\V
â€¢3HULRFXODULQMHFWLRQRIDQ\FRUWLFRVWHURLG
VROXWLRQ
6WXG\VWDIIZLOOFRQILUPWKDWWKHSDWLHQWKDVQRW
XVHGSULRUWR'D\IRUWKHLQGLFDWHGZDVKRXW
LQWHUYDODQGIRUWKHGXUDWLRQRIWKHVWXG\DQ\RI
WKHIROORZLQJGLVDOORZHGPHGLFDWLRQVV\VWHPLFDOO\RULQWKHVWXG\H\HJURXSHGE\
ZDVKRXWSHULRG
Â«
GD\V
â€¢6\VWHPLFFRUWLFRVWHURLGV
â€¢6\VWHPLFDQDOJHVLFVSDLQUHOLHYHUV
HJJDEDSHQWLQSUHJDEDOLQ16$,'VDQGRSLRLGV
1RWH 8VH RI DFHWDPLQRSKHQ XS WR
PJGD\DQGÂµEDE\Â¶DVSLULQXS
WR  PJGD\ GXULQJ WKH VWXG\ DUH
DOORZHG 8VH RI DQ RSLRLG GXULQJ
FDWDUDFWVXUJHU\LVDOORZHG

GD\V
â€¢3HULRFXODULQMHFWLRQRIDQ\
FRUWLFRVWHURLGVROXWLRQ
57$2SKWKDOPLF6XVSHQVLRQ 5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO& $PHQGPHQW)HE

&RQILGHQWLDO  3DJHRI â€¢0HGLFDWLRQVIRU%3+WDPVXORVLQ
VLORGRVLQDOIX]RVLQILQDVWHULGH
6HFWLRQ $GPLQLVWUDWLYH
XSGDWHâ€¢*ODXFRPDPHGLFDWLRQVRURFXODUK\SHUWHQVLRQ
PHGLFDWLRQVLQWKHVWXG\H\H
â€¢2FXODUK\SHUWHQVLRQPHGLFDWLRQVLQWKHVWXG\
H\H
Â«
â€¢9LWUHFWRP\ SURFHGXUH LQ DGGLWLRQ WR WKH
FDWDUDFWH[WUDFWLRQSURFHGXUHLQWKHVWXG\H\H
â€¢,IDSDWLHQWXVHVDGLVDOORZHGPHGLFDWLRQWKLV
ZLOOEHUHFRUGHGDVDSURWRFROYLRODWLRQâ€¢6\VWHPLFPHGLFDWLRQVIRUEHQLJQSURVWDWLF
K\SHUSODVLD %3+ HJ WDPVXORVLQ
VLORGRVLQDOIX]RVLQILQDVWHULGH
â€¢6\VWHPLF $QDOJHVLFVSDLQ UHOLHYHUV
LQFOXGLQJRSLRLGVQDUFRWLFVDQGRWKHUSDLQ
PHGLFDWLRQVV\VWHPLFDOO\HJJDEDSHQWLQSUHJDEDOLQ16$,'V DQGRSLRLGV
â€¢1RWH8VHRIDFHWDPLQRSKHQXSWR
P J  G D \  D Q G Âµ E D E \ Â¶ D V S L U L Q  X S W R   
PJGD\GXULQJWKHVWXG\DUHDOORZHG8VH
RI DQ RSLRLG GXULQJ FDWDUDFW VXUJHU\ LV
DOORZHG
â€¢*ODXFRPD PHGLFDWLRQV RU RFXODU
K\SHUWHQVLRQPHGLFDWLRQV LQWKHVWXG\H\H
â€¢
2FXODUK\SHUWHQVLRQPHGLFDWLRQVLQWKHVWXG\
H\H
Â«
â€¢$Q\RWKHURSKWKDOPLFVXUJLFDOSURFHGXUH
HJ YLWUHFWRP\ UHOD[LQJ LQFLVLRQV
LULGHFWRP\FRQMXQFWLYDOH[FLVLRQVXVHRILULV KRRNV RU RWKHU LULV GLODWRUV HWF
9LWUHFWRP\ SURFHGXUH LQ DGGLWLRQ WR WKH
FDWDUDFW H[WUDFWLRQ SURFHGXUH DQG 3&,2/
LPSODQWDWLRQ LQWKHVWXG\H\H
â€¢3ODQWRKDYHODVHURULQFLVLRQDOVXUJHU\LQ
WKH VWXG\ H\H RWKHU WKDQ FDWDUDFW
VXUJHU\
57$2SKWKDOPLF6XVSHQVLRQ 5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO& $PHQGPHQW)HE

&RQILGHQWLDO  3DJHRI â€¢6XUJHU\ SODQQHG RU VFKHGXOHG IRU WKH
FRQWUDODWHUDOH\H
,IDSDWLHQWXVHVDGLVDOORZHGPHGLFDWLRQWKLV XVH
ZLOOEHUHFRUGHGDVDSURWRFROYLRODWLRQ 
6HFWLRQ $GGLWLRQDOGHWDLOV
VSHFLILHGIRU
HVFDSH
PHGLFDWLRQV8VHRIHVFDSHPHGLFDWLRQVVKRXOGEHDYRLGHGLI
SRVVLEOH,IHVFDSHPHGLFDWLRQLVJLYHQWKHVWXG\
GUXJVKRXOGEHGLVFRQWLQXHGDQGWKHSDWLHQWVKRXOG
UHPDLQLQWKHVWXG\DQGIROORZHGSHUWKHSURWRFRO
WRWKHHQGRIWKHVWXG\8VHRIHVFDSHPHGLFDWLRQVVKRXOGEHDYRLGHGLI
SRVVLEOH,I LQWKHLQYHVWLJDWRUÂ¶VDVVHVVPHQW 
HVFDSHPHGLFDWLRQLV UHTXLUHGJLYHQGXHWRODFN
RIHIILFDF\ WKHVWXG\GUXJVKRXOGEHGLVFRQWLQXHG
SULRUWRDGPLQLVWUDWLRQRI WKHILUVWGRVHRI
HVFDSHPHGLFDWLRQ DQG7KHSDWLHQWVKRXOG
UHPDLQLQWKHVWXG\ DQGFRQWLQXHWREH IROORZHG
SHUWKHSURWRFRO IRUDOOUHPDLQLQJYLVLWVDQG
DVVHVVPHQWV WRWKHHQGRIWKHVWXG\ 7KHVH
SDWLHQWVZKRUHTXLUHHVFDSHPHGLFDWLRQVKRXOG
EHFRQVLGHUHGDVGLVFRQWLQXHGIURPVWXG\
PHGLFDWLRQGXHWRODFNRIHIILFDF\DQGWKHHVFDSHPHGLFDWLRQVXVHGPXVWEHGRFXPHQWHG
LQWKHH&5) 
6HFWLRQ
6XEEXOOHW3LQ
+ROH9LVXDO
$FXLW\8WLOL]LQJ
DQ(7'56&KDUW$GPLQLVWUDWLYH
XSGDWH3DWLHQWVPXVWKDYHDSRWHQWLDOSRVWRSHUDWLYHSLQ
KROH9$RIJUHDWHUWKDQORJ0$5LQWKH
RSHUDWLYHH\HDQGLQWKHIHOORZH\HDVPHDVXUHG
XVLQJDQ(7'56FKDUW3DWLHQWVPXVWKDYHDSRWHQWLDOSRVWRSHUDWLYHSLQ
KROH9$RIJUHDWHUWKDQ ORJ0$5LQWKH
RSHUDWLYHH\HDQGLQWKHIHOORZH\HDVPHDVXUHG
XVLQJDQ(7'56FKDUW
6HFWLRQ $GPLQLVWUDWLYH
XSGDWH7KHVHYLVLWVPD\EHSHUIRUPHGLQRUGHUWRHQVXUH
SDWLHQWVDIHW\$OOLQIRUPDWLRQJDWKHUHGDWXQVFKHGXOHGYLVLWVVKRXOGEHUHFRUGHGRQWKH
8QVFKHGXOHG9LVLW(DUO\([LW9LVLWSDJHVRIWKH
6RXUFH'RFXPHQWDQGFRUUHVSRQGLQJH&5)
,IDUDQGRPL]HGSDWLHQWGRHVQRWDWWHQGWKHLU
VFKHGXOHGYLVLWWKHH&5)SDJHVIRUWKHPLVVHGYLVLW7KHVHYLVLWVPD\EHSHUIRUPHGLQRUGHUWRHQVXUH
SDWLHQWVDIHW\$OOLQIRUPDWLRQJDWKHUHGDWXQVFKHGXOHGYLVLWVVKRXOGEHUHFRUGHGRQWKH
8QVFKHGXOHG9LVLW(DUO\([LW9LVLWSDJHVRIWKH
6RXUFH'RFXPHQWDQGFRUUHVSRQGLQJH&5)
,IDUDQGRPL]HGSDWLHQWGRHVQRWDWWHQGWKHLU
VFKHGXOHGYLVLWWKHH&5)SDJHVIRUWKHPLVVHG
RTA 408 Ophthalmic Suspension  Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307  Amendment 1 : 10-Feb-2014 
 
Confidential   Page 69 of 77 will be skip ped.  
All efforts should be made to schedule patients for 
an Exit Visit to complete Exit Procedures.  visit will be skipped.  
All efforts should be made to schedule patients for an Exit Visit to complete Exit Procedures. 
Information from Early Exit Visits should be 
recorded on the Visit 6/Exit Visit pages.  
Section 8.5  Administrative 
update Patients will be provided with a study drug compliance diary to document BID dosing for 14 
days. Patient compliance with dosing will be 
assessed by in -office review of study drug 
compliance diary. Patients who miss more than 25% of their study drug doses ( more than 7 doses) 
will be considered non-compliant with dosing and a protocol deviation should be recorded. Patients will be provided with a study drug 
compliance diary to document BID dosing for 14 
days. Patient compliance with dosing will be 
assessed by in -offic e review of study drug 
compliance diary. Patients who miss more than 
25% of their study drug doses ( more than 7 total  
doses) will be considered non -compliant with 
dosing and a protocol deviation should be 
recorded.  
Section 8.6.1  
Completed 
Patients  Adminis trative 
update A completed patient is one who has not been 
discontinued from the study. A completed patient is one who has not been discontinued from the study and continues study 
assessments through Visit 6 (Day 21) . 
Section 8.6.2  
Discontinued 
Patients  Administrative 
update Patients may be discontinued prior to their completion of the study due to any of the following reasons:  
â€¦ 
Notification of a patientâ€™s discontinuation and the 
reason for discontinuation will be made to CRO 
and study Sponsor and will be clearly documented on the eCRF.  Patients may be discontinued from the study 
prior to their completion of the study due to any of the following reasons: 
â€¦ 
Notification of a patientâ€™s discontinuation of 
study drug administration and the reason for 
discontinuation will be made to CRO and study Sponsor and will be clearly documented 
on the eCRF.  Patients who receive escape 
medication are to discontinue study d rug 
administration and are to remain in the study 
and be followed per the protocol to the end of 
57$2SKWKDOPLF6XVSHQVLRQ 5HDWD3KDUPDFHXWLFDOV
&OLQLFDO7ULDO3URWRFRO& $PHQGPHQW)HE

&RQILGHQWLDO  3DJHRI WKHVWXG\3DWLHQWVZKRGLVFRQWLQXHVWXG\
GUXJDGPLQLVWUDWLRQIRURWKHUUHDVRQVDUH
HQFRXUDJHGWRUHPDLQLQWKHVWXG\DQGFRQWLQXHZLWKVWXG\DVVHVVPHQWVWKURXJKWKH
HQGRIWKHVWXG\
1RWLILFDWLRQRIDSDWLHQWÂ¶VGLVFRQWLQXDWLRQ RI
VWXG\SDUWLFLSDWLRQ DQGWKHUHDVRQIRU
GLVFRQWLQXDWLRQZLOOEHPDGHWR&52DQGVWXG\6SRQVRUDQGZLOOEHFOHDUO\GRFXPHQWHGRQWKH
H&5)
6HFWLRQ 6SRQVRU
3KDUPDFRYLJLODQFH
ZLOODVVHVVIRU
H[SHFWHGQHVV
7KHH[SHFWHGQHVVRIDQ$(VKRXOGEHGHWHUPLQHG
EDVHGXSRQH[LVWLQJVDIHW\LQIRUPDWLRQDERXWWKH
VWXG\GUXJXVLQJWKHVHH[SODQDWLRQV
â€¢8QH[SHFWHG DQ$(WKDWLVQRWOLVWHGLQWKH
,%RULVQRWOLVWHGDWWKHVSHFLILFLW\RU
VHYHULW\WKDWKDVEHHQREVHUYHG
â€¢([SHFWHGDQ$(WKDWLVOLVWHGLQWKH,%DW
WKHVSHFLILFLW\DQGVHYHULW\WKDWKDVEHHQREVHUYHG
â€¢1RWDSSOLFDEOH $Q$(XQUHODWHGWRWKH
VWXG\GUXJ
$(VWKDWDUHPHQWLRQHGLQWKH,%DVRFFXUULQJZLWK
DFODVVRIGUXJVRUDVDQWLFLSDWHGIURPWKHSKDUPDFRORJLFDOSURSHUWLHVRIWKHGUXJEXWDUHQRW
VSHFLILFDOO\PHQWLRQHGDVRFFXUULQJZLWKWKHWKH
SDUWLFXODUGUXJXQGHULQYHVWLJDWLRQDUHWREH
FRQVLGHUHGXQH[SHFWHG7KHH[SHFWHGQHVVRIDQ$(VKRXOGEHGHWHUPLQHG
EDVHGXSRQH[LVWLQJVDIHW\LQIRUPDWLRQDERXWWKH
VWXG\GUXJXVLQJWKHVHH[SODQDWLRQV
â€¢8QH[SHFWHG DQ$(WKDWLVQRWOLVWHGLQ
WKH,%RULVQRWOLVWHGDWWKHVSHFLILFLW\RU
VHYHULW\WKDWKDVEHHQREVHUYHG
â€¢([SHFWHGDQ$(WKDWLVOLVWHGLQWKH,%DW
WKHVSHFLILFLW\DQGVHYHULW\WKDWKDVEHHQ
REVHUYHG
â€¢1RWDSSOLFDEOH $Q$(XQUHODWHGWRWKH
VWXG\GUXJ
$(VWKDWDUHPHQWLRQHGLQWKH,%DVRFFXUULQJ
ZLWKDFODVVRIGUXJVRUDVDQWLFLSDWHGIURPWKH
SKDUPDFRORJLFDOSURSHUWLHVRIWKHGUXJEXWDUH
QRW VSHFLILFDOO\ PHQWLR QHG DV RFFXUULQJ ZLWK
WKHWKHSDUWLFXODUGUXJXQGHULQYHVWLJDWLRQDUHWR
EHFRQVLGHUHGXQH[SHFWHG
6HFWLRQ
3DUDJUDSK$GPLQLVWUDWLYH
XSGDWH,IWKH,QYHVWLJDWRUEHFRPHVDZDUHRIDQ\QHZ
LQIRUPDWLRQUHJDUGLQJDQ6$(LHUHVROXWLRQ,IWKH,QYHVWLJDWRUEHFRPHVDZDUHRIDQ\QHZ
LQIRUPDWLRQUHJDUGLQJDQ6$(LHUHVROXWLRQ
RTA 408 Ophthalmic Suspension  Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307  Amendment 1 : 10-Feb-2014 
 
Confidential   Page 71 of 77 change in condition, or new treatment), a new 
SAE/Unanticipated Report Form must be 
completed and faxed to CRO within 24 hours of the siteâ€™s awareness of the event.  change in condition, or ne w treatment), a new 
SAE/Unanticipated Report Form must be completed and faxed to the Sponsor or designee  
CRO  within 24 hours of the siteâ€™s awareness of 
the event.  
Section 10.6  Administrative 
update If in addition to a statistically significant test of the  
difference in the proportion of study eyes with absence of anterior chamber cells at Visit 5 (Day 
15) in favor of the 1.0% concentration of RTA 408 
Ophthalmic Suspension, the test of the difference in the proportion of study eyes with absence of 
ocular pa in at Visit 3 (Day 4) is statistically 
significant in favor of the 1.0% RTA 408 Ophthalmic Suspension, then the 1.0% 
concentration of RTA 408 Ophthalmic Suspension will be declared to be superior to placebo in both 
the proportion of study eyes with absence of 
anterior chamber cells at Visit 5 (Day 15) and the 
proportion of study eyes with absence of ocular 
pain at Visit 3 (Day 4).   
OR 
If in addition to a statistically significant test of the difference in the proportion of study eyes with 
absence of anterior chamber cells at Visit 5 (Day 
15) in favor of the 0.5% concentration of RTA 408 
Ophthalmic Suspension, the test of the difference 
in the proportion of study eyes with absence of ocular pain at Visit 3 (Day 4) is statistically 
significant in favor of the  0.5% RTA 408 
Ophthalmic Suspension, then the 0.5% concentration of RTA 408 Ophthalmic Suspension 
will be declared to be superior to placebo in both If in addition to a statistically significant test of 
the difference in the proportion of study eyes with 
absence of anterior chamber cells at Visit 5 (Day 
15) in favor of the 1.0% concentration of RTA 
408 Ophthalmic Suspension, the test of the 
difference in the proportion of study eyes with 
absence of ocular pain at Visit 3 (Day 4) is 
statistically significant in favor of the 1.0% RTA 
408 Ophthalmic Suspension, then the 1.0% 
concentration of RTA 408 Ophthalmic 
Suspension will be declared to be superior to 
placebo in both the proportion of study eyes with 
absence of anterior chamber cells at Visit 5 (Day 
15) and the proportion of study eyes with absence 
of ocular pain at Visit 3 (Day 4).   
OR 
If in addition to a statistically significant test of 
the differen ce in the proportion of study eyes 
with absence of anterior chamber cells at Visit 5 
(Day 15) in favor of the 0.5% concentration of 
RTA 408 Ophthalmic Suspension, the test of the 
difference in the proportion of study eyes with 
absence of ocular pain at Visit 3 (Day 4) is 
statistically significant in favor of the 0.5% RTA 
408 Ophthalmic Suspension, then the 0.5% 
concentration of RTA 408 Ophthalmic 
Suspension will be declared to be superior to 
RTA 408 Ophthalmic Suspension  Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307  Amendment 1 : 10-Feb-2014 
 
Confidential   Page 72 of 77 the proportion of study eyes with absence of 
anterior chamber cells at Visit 5 (Day 15) and the 
proportion of study eyes with absence of ocular pain at Visit 3 (Day 4).   placebo in both the proportion of study eyes with 
absence of anterior chamber cells at Visit 5 (Day 
15) and the proportion of study eyes with absence 
of ocular pain at Visit 3 (Day 4).   
Section 10.10  Administrative 
update If in addition to a statistically significant test of the difference in the proportion of study ey es with 
absence of anterior chamber cells at Visit 5 (Day 15) in favor of the 1.0% concentration of RTA 408 
Ophthalmic Suspension, the test of the difference 
in the proportion of study eyes with absence of ocular pain at Visit 3 (Day 4) is statistically 
significant in favor of the 1.0% RTA 408 
Ophthalmic Suspension, then the 1.0% concentration of RTA 408 Ophthalmic Suspension 
will be declared to be superior to placebo in both the proportion of study eyes with absence of 
anterior chamber cells at Visit 5 (Day 15) and the 
proportion of study eyes with absence of ocular 
pain at Visit 3 (Day 4).   
OR 
If in addition to a statistically significant test of the difference in the proportion of study eyes with 
absence of anterior chamber cells at Visit 5 (Day 
15) in favor of the 0.5% concentration of RTA 408 
Ophthalmic Suspension, the test of the difference 
in the proportion of study eyes with absence of 
ocular pain at Visit 3 (Day 4) is statistically significant in favor of the 0.5% RTA 408 
Ophthalmic Suspension, then the 0.5% 
concentration of RTA 408 Ophthalmic Suspension 
will be declared to be superior to placebo in both 
the proportion of study eyes with absence of If in addition to a statistically significant test of 
the difference in the proportion of study eyes with 
absence of anterior chamber cells at Visit 5 (Day 
15) in favor of the 1.0% concentration of RTA 
408 Ophthalmic Suspension, the test of the 
differen ce in the proportion of study eyes with 
absence of ocular pain at Visit 3 (Day 4) is 
statistically significant in favor of the 1.0% RTA 
408 Ophthalmic Suspension, then the 1.0% 
concentration of RTA 408 Ophthalmic 
Suspension will be declared to be superior to 
placebo in both the proportion of study eyes with 
absence of anterior chamber cells at Visit 5 (Day 
15) and the proportion of study eyes with absence 
of ocular pain at Visit 3 (Day 4).   
OR 
If in addition to a statistically significant test of 
the diffe rence in the proportion of study eyes with 
absence of anterior chamber cells at Visit 5 (Day 
15) in favor of the 0.5% concentration of RTA 
408 Ophthalmic Suspension, the test of the 
difference in the proportion of study eyes with 
absence of ocular pain at Visit 3 (Day 4) is 
statistically significant in favor of the 0.5% RTA 
408 Ophthalmic Suspension, then the 0.5% 
concentration of RTA 408 Ophthalmic 
Suspension will be declared to be superior to 
placebo in both the proportion of study eyes with 
RTA 408 Ophthalmic Suspension  Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307  Amendment 1 : 10-Feb-2014 
 
Confidential   Page 73 of 77 anterior chamber cells at Visit 5 (Day 15) and the 
proportion of study eyes with absence of ocular 
pain at Visit 3 (Day 4).   
If in addition to a statistically significant test of the 
difference in the proportion of study eyes with 
absence of anterior chamber cells at Visit 5 (Day 
15) in favor of the 1.0% concentration of RTA 408 
Ophthalmic Suspension, the anterior chamber cells at Visit 5 (Day 15) is statistically significant in 
favor of the 0.5% concentration of RTA 408 
Ophthalmic Suspension, then both concentrations 
of RTA 408 Ophthalmic Suspension will be 
declared to be superior to placebo in the proportion of study eyes with absence of anterior chamber 
cells at Visit 5 (Day 15).  
Finally, if a statistically significant test of the difference in the proportion of study eyes with 
absence of anterior chamber cells at Visit 5 (Day 
15) in favor of the 0.5% concentration of RTA 408 
Ophthalmic Suspension, the test of the difference in the proportion of study eyes with absence of 
ocular pain at Visit 3 (Day 4) is statistically 
significant in favor of the 0.5% RTA 408 
Ophthalmic Suspension, then the 0.5% 
concentrat ion of RTA 408 Ophthalmic Suspension 
will be declared to be superior to placebo in both 
the proportion of study eyes with absence of 
anterior chamber cells at Visit 5 (Day 15) and the 
proportion of study eyes with absence of ocular 
pain at Visit 3 (Day 4).   absence of an terior chamber cells at Visit 5 (Day 
15) and the proportion of study eyes with absence 
of ocular pain at Visit 3 (Day 4).   
If in addition to a statistically significant test of 
the difference in the proportion of study eyes with 
absence of anterior chamber cells at Visit 5 (Day 
15) in favor of the 1.0% concentration of RTA 
408 Ophthalmic Suspension, the anterior chamber 
cells at Visit 5 (Day 15) is statistically significant 
in favor of the 0.5% concentration of RTA 408 
Ophthalmic Suspension, then both concentrations 
of RTA 408 Ophthalmic Suspension will be 
declared to be superior to placebo in the 
proportion of study eyes with absence of anterior 
chamber cells at Visit 5 (Day 15).  
Finally, if a statistically significant test of the 
difference in the proportion of study eyes with 
absence of anterior chamber cells at Visit 5 (Day 
15) in favor of the 0.5% concentration of RTA 
408 Ophthalmic Suspension, the test of the 
difference in the proportion of study eyes with 
absence of ocular pain at Visit 3 (Day 4 ) is 
statistically significant in favor of the 0.5% RTA 
408 Ophthalmic Suspension, then the 0.5% 
concentration of RTA 408 Ophthalmic 
Suspension will be declared to be superior to 
placebo in both the proportion of study eyes with 
absence of anterior chamber  cells at Visit 5 (Day 
15) and the proportion of study eyes with absence 
of ocular pain at Visit 3 (Day 4).   
Section 10.11  Administrative 
update The secondary efficacy variables will be 
summarized and analyzed at Days 4, 8, and 21 for The secondary efficacy variables will be 
summarized  and analyzed  at Days 4, 8, and 21 for 
RTA 408 Ophthalmic Suspension  Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307  Amendment 1 : 10-Feb-2014 
 
Confidential   Page 74 of 77 absence of anterior  chamber cells and at Days 8, 15 
and 21 for absence of ocular pain, similarly to the 
primary efficacy summaries and analyses. Additionally, anterior chamber cell grade and 
ocular pain score at each visit and change from 
baseline will be summarized using co ntinuous and 
discrete summary statistics.  
Absence of anterior chamber flare and anterior chamber flare grade and the sum of anterior 
chamber cell and flare grade, including absence of 
both anterior chamber cell and flare will be 
summarized and analyzed sim ilarly to anterior 
chamber cells and pain at each visit.  absence of anterior chamber cells and at Days 8, 
15 and 21 for absence of ocular pain, similarly to 
the prima ry efficacy summaries and analyses. 
Additionally, anterior chamber cell grade and 
ocular pain score at each visit and change from 
baseline will be summarized using continuous 
and discrete summary statistics.  
Absence of anterior chamber flare and anterior 
chamber flare grade and the sum of anterior 
chamber cell and flare grade, including absence 
of both anterior chamber cell and flare will be 
summarized  and analyzed  similarly to anterior 
chamber cells and pain at each visit.  
Appendix 1  
Ocular Pain 
Grading Scale 
(Study Eye)  Administrative 
update  Ocular Pain will be assessed by the patient at 
screening and at each follow -up visit, utilizing a 
Numerical Pain Rating Scale1 graded from 0 to 10. 
Patients will assess the level of pain they are experiencing in the  study eye at the time of the 
assessment.  
The examiner will ask the patient the following question: 
On a scale of 0 to 10, in which 0 is no pain 
and 10 is the worst possible or unbearable 
pain, please mark on the scale the number that 
best describes the pain or discomfort you are 
feeling in the operated* eye at this time. The middle of the scale (around 5) can be used to describe â€œmoderate painâ€.  
*At the screening assessment visit, the patient will 
be asked about the eye scheduled for surgery.  Ocular Pain will be assessed by the patient at screening and at each follow -up visit, utilizing a 
Numer ical Pain Rating Scale
1 graded from 0 to 
10. Patients will assess the level of pain they are experiencing in the study eye at the time of the 
assessment. Patients may only select whole 
numbers on the scale.   
The examiner will ask the patient the following question related to Figure 1: 
On a scale of 0 to 10, in which 0 is no pain and 10 is the worst possible or unbearable 
pain, please mark on the scale the whole  
number that best describes the pain or discomfort you are feeling in the operated* 
eye at this time. The middle of the scale 
(around 5) can be used to describe 
â€œmoderate painâ€.  
RTA 408 Ophthalmic Suspension  Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307  Amendment 1 : 10-Feb-2014 
 
Confidential   Page 75 of 77 1 Reference  4. Numeric Pain Rating Scale (NPRS). 
National Institutes of Health (NIH), Warren Grant 
Magnuson Clinical Center. Pain Intensity Instruments. July 2003.  Figure 1  Ocular Pain Grading Scale  
â€¦ 
*At the screening assessment visit, the patient 
will be asked about the eye scheduled for surgery.  
1 Reference 4. National Institutes of Health (NIH).  Numeric Pain Rating Scale 
(NPRS). National Institutes of Health 
(NIH), . Warren Grant Magnuson Clinical 
Center. Pain Intensity Instruments. July 
2003. 
Appendix 2  
Footnote #4 Administrative 
update In case of early termination or if patient did not return study drug at prior to Visit 5. In case of early termination or if patient did not 
return study drug at  prior to Visit 5. 
Appendix 3  Rationale for 
Amendment 1 and 
the Table of 
Changes was 
inserted  Not applicable.  [Rationale for amendment 1 and the table of 
changes was inserted]  
Appendix 4  Administrative 
update  Protocol Number: 408-C-1307 Protocol Number: 408-C-1307 Amendment 1  
Appendix 4  Administrative 
update  Final Date: 21 -Nov-2013 Final Date: 10-Feb-2014  
Appendix 5  Administrative 
update  Protocol Number: 408-C-1307 Protocol Number: 408-C-1307 Amendment 1  
Appendix 5  Administrative 
update  Final Date: 21 -Nov-2013 Final Date: 10-Feb-2014  
RTA 408 Ophthalmic Suspension      Reata Pharmaceuticals  
Clinical Trial Protocol: 408 -C-1307      Amendment 1 : 10-Feb-2014 
 
Confidential   Page 77 of 77 APPENDIX 5 :  INVESTIGATOR â€™S SIGNATURE  
Protocol Title:  A Multicenter, Randomized, Dose-Ranging, Double-Masked, 
Placebo  Controlled Phase 2 Study Evaluating the Safety and 
Efficacy of RTA 408 Ophthalmic Suspension  for the Treatment 
of Ocular Inflammation and Pain following Ocular Surgery 
Protocol Number:  408-C-1307 Amendment 1 
Final Date: 10-Feb-2014 
I agree to i mplement and conduct the study diligently and in strict compliance with the 
protocol, good clinical practices and all applicable laws and regulations.  I agree to 
mainta in all information supplied by CRO  and the Sponsor in confidence and, when this 
information is submitted to an Institutional Review Board (IRB), Ethical Review Committee (ERC) or another group, it will be submitted with a designation that the 
material is confidential.  
I have read this protocol in its entirety, including the above statement, and I agree to all 
aspects.  
Signed:   Date:    
<enter name and credentials> <enter title>  
<enter affiliation>  
<enter address>  
<enter phone number> 